Peripheral blood stem cells in haematological malignancies by Craig, Jenny I.O.
PERIPHERAL BLOOD STEM CELLS IN
HAENATOLOGICAL MALIGNANCIES
by
Jenny I. 0. Craig
MB, ChB, MRCP(UK)
A thesis submitted for the degree of Doctor of Medicine










1.1. Haematopoietic stem cells 1
1.2. The role of transplantation in
haematological malignancies 4
1. Lymphoma 4
2. Acute leukaemia 5
1.3. Complications of BMT 6
1.4. Peripheral blood stem cells 7
1. PBSC in animals 7
2. PBSC in man 8
1.5. Stem cell mobilisation 9
1.6. PBSC Autografting 11
1. Early studies 11
2. PBSCT in leukaemaia 12
3. PBSCT in lymphoma 13
4. PBSCT in myeloma 14
i
1.7. Advantages of PBSC 14
1. Collection of PBSC 14
2. Rapid haematopoietic reconstitution 16
3. Lower tumour contamination 16
1.8 Disadvantages of PBSC 17
1. CFU-GM dose 17
2. PBSC mobilisation and prediction of flux 19
3. Quality of PBSC 19
1.9. Tumour contamination of PBSCH 20
1. Immunological genes 21
2. Gene rearrangement studies 24
1.10. Aims 25
CHAPTER 2 PERIPHERAL BLOOD STEM CELLS AFTER
CHEMOTHERAPY
2.1. Materials 27




1. CFU-GM assay 34
2. Preparation of PHA LCM 34
3. Analysis of colony cell types 35
4. Expression of CFU-GM results 36
5. Blood cell counting 36
6. Statistics 36
2.4 Results 37
1. Morphology of CFU-GM colonies 37
ii
2. Effect of MNC plating concentration 37
3. CFU-GM in a normal population 37
4. CFU-GM in patients with lymphoma 37
1. NHL 37
2. HD 43
3. Effect of marrow involvement 49
4. Effect of second line chemotherapy 49
5. Effect of course number 49
5. CFU-GM in acute leukaemia 53
1. AML 53
2. ALL 53
3. Predictors of CFU-GM peak 58
6. CFU-GM in myeloma 58
2.5. Conclusion 61





2. Secondary processing and cryopreservation 65
3. Assessment of pellet viability 66
3.4. Results 67
1. PBSCH Product 67
2. Effects of PBSC harvesting on patients 67
3. Effects of secondary processing 69
4. PBSCH in patients with lymphoma 69








CHAPTER 4 GENE REARRANGEMENT STUDIES
4.1. Materials 78
4.2. Patients 82
1. Tumour and presentation blood 82
2. PBSCH 83
4.3. Methods 85
1. DNA isolation 85
1. Blood and bone marrow 85
2. MNC 86
3. Tissue samples 86
2. DNA digestion 87
3. Gel electrophoresis 87
4. Southern Blotting 87
5. Probes 88
6. Prehybridisation, hybridisation and
washing 89
7. Autoradiography 90
8. Re-probing a filter 91
4.4. Results 91
1. Tumours 91
1. Acute leukaemias 91
2. Lymphomas 91





5.1. The CFU-GM assay 103
1. Standardisation of the CFU-GM assay
system 104
2. Future improvements in PBSC
identification 106
5.2 PBSC after chemotherapy 107
1. Acute leukaemia 108
2. Lymphoma 110
3. Myeloma 112
5.3 Other approaches to PBSC mobilisation 113
5.4. PBSCH 115
1. Clinical problems 115
2. Product specification 117
3. Advances 117
4. Secondary processing 119
5. Pellet viabilities 120
6. Progenitors harvested 121
1. Lymphoma 121
2. Acute leukaemia 122
5.5. Gene rearrangements in haematological
malignancies 123
1. Acute leukaemia 124
2. Lymphoma 124
5.6. Gene rearrangements in NHL presentation
blood 126
V
5.7. Tumour contamination of PBSCH 127
5.8. Concluding remarks 129
References 132
Appendix 1 Presentations and publications 151
TABLES
CHAPTER 2
Table 2.1 Characteristics of patients
receiving chemotherapy 29
2 .11 NHL chemotherapy regimes 31
2.Ill HD chemotherapy regimes 32
2. IV Acute leukaemia chemotherapy
regimes 33
2.V CFU-GM after chemotherapy for NHL 45
2 .VI CFU-GM after chemotherapy for HD 48
2.VII CFU-GM after CHOP 52
2.VIII CFU-GM after chemotherapy for
acute leukaemia 56
2.IX Blood parameters during CFU-GM
peak 60
CHAPTER 3
TABLE 3.1 Patients undergoing PBSCH 64
3.II PBSCH product 68
3.Ill Lymphoma PBSCH 70
3. IV Acute leukaemia and myeloma PBSCH 73
CHAPTER 4
Table 4.1 Patients 84



















Gene rearrangements in PBSCH
in HD & AML 98
Gene rearrangements in PBSCH
in ALL, NHL & myeloma 99
IgHJ recombination 23
CFU-GM colony in culture 38
CFU-GM colony stained MGG 39
CFU-GM colony stained CE 40
Effect of MNC plating concentration
on CFU-GM in normals 41
Effect of MNC plating concentration
on CFU-GM in PBSCH 42
CFU-GM in NHL after chemotherapy 44
CFU-GM response in a patient with
NHL treated with BCHOPM 46
CFU-GM in HD after chemotherapy 47
Effect of bone marrow involvement
on CFU-GM peak 50
Effect of 2nd line chemotherapy
on CFU-GM peak 51
CFU-GM in leukaemia and myeloma
after chemotherapy 54
CFU-GM response in a patient with













Effect of successive courses of
DAT & ADE on CFU-GM 57
Peak CFU-GM and rate of white cell
count recovery 59
PBSCH CFU-GM after 1st & 2nd line
chemotherapy 71
CFU-GM recoveries from PBSCH pellets
after storage 75
Comparison of CFU-GM from pellets with
growth from PBSCH at transplant 76
Autoradiograph of DNA from patients
with AML probed with TCR6 94
Autoradiograph of DNA from a patient
with ALL probed with IgHJ 95
Autoradiograph of DNA from a patient
with NHL probed with IgHJ 101
Autoradiograph of DNA from a patient
with NHL probed with TCR/3 102
viii
DECLARATION
I declare that this written thesis is my own work,
planned, coordinated and performed by myself or under my




ACD-A Anticoagulant citrate dextrose - solution A
ALL Acute lymphoblastic leukaemia
AML Acute myeloid leukaemia
BMT Bone marrow transplantation
CE Combined esterase
CFU-C Colony forming unit - culture
CFU-GM Colony forming unit - granulocyte monocyte
CFU-mix Colony forming unit - granulocyte erythroid
monocyte megakaryocyte (pluripotential CFU)
CFU-S Colony forming unit - spleen
CML Chronic myeloid leukaemia




EFS Event free survival
FAB French American British cooperative group
FCS Foetal calf serum
G-CSF Granulocyte colony stimulating factor
GM-CSF Granulocyte macrophage colony stimulating
factor
GVHD Graft versus host disease
HBSS Hank's buffered saline solution
HD Hodgkin's disease
HLA Histocompatability locus antigen
X
IgH Immunoglobulin heavy chain
IgHJ Immunoglobulin heavy chain joining region
IMDM Iscove's modified Dulbeccos medium
LCM Lymphocyte conditioned medium
LFS Leukaemia free survival
MGG May Grunwald Giemsa
MIC Morphologic immunologic & cytogenetic
MNC Mononuclear cells
MRC Medical research council
NHL Non Hodgkin's lymphoma
PBSC Peripheral blood stem cells
PBSCH Peripheral blood stem cell harvest
PBSCT Peripheral blood stem cell tranplant
PCR Polymerase chain reaction
PHA Phytohaemagluttinin
Ph' Philadelphia chromosome
SEM Standard error of the mean
TCR T cell receptor
WCC White cell count
xi
ACKNOWLEDGEMENTS
The diagnosis and management of patients with
haematological malignancies depends upon a team of
dedicated professionals. I am most grateful to Dr A C
Parker, consultant haematologist, who leads this team and
whose vision and encouragement enabled this research to
be undertaken.
I am indebted to all the patients involved who willingly
participated and encouraged me in this work. To my
medical and nursing colleagues in the Royal Infirmary of
Edinburgh and to Dr C J McCallum, consultant
haematologist in Fife I extend my gratitude for help in
obtaining samples. The PBSCH were performed in the cell
separator unit of the South East Scotland Blood
Transfusion Service under the care of Dr J Gillon and by
Sister A Stewart and her expert nursing colleagues. My
special thanks must go to Staff Nurse Moira Grant who
assisted with PBSCH and specific care of the patients in
the study. The MLSO staff in the department of
Haematology, RIE processed and cryopreserved the PBSCH
and gave technical support whenever help was needed.
The mainstay of support came from my colleagues in the
Kay Kendall research laboratory in haematology, RIE.
Susan Smith, Kenneth Langlands and Anne Anderson
comprised a team of workers who gave unending assistance
to enable the studies to come to fruition. To Dr Robert
Anthony, senior scientist, I am forever indebted for
xii
teaching me the ways of science, guiding me through the
peaks and many troughs of research and ultimately
delivering me safely back to clinical medicine.
I acknowledge the University of Edinburgh for awarding me
a faculty fellowship to carry out this research and the
support of the Kay Kendall leukaemia trust.
Finally, to my husband Mark and son Fraser, who managed




Autologous BMT is used successfully as intensive therapy
for patients with haematological malignancies and other
solid tumours. Peripheral blood contains haematopoietic
progenitors whose levels are greatly increased during
very early remission after treatment for acute leukaemia
or after high dose chemotherapy schedules. These
circulating progenitors have been harvested by
leucapheresis and used as an alternative to bone marrow
as salvage after myelo-ablative treatments. PBSC appear
to have several advantages over bone marrow including
rapid haematopoietic reconstitution after
transplantation, the ability to collect PBSC without a
general anaesthetic and in the presence of bone marrow
abnormalities and the possibilty of minimal tumour
contamination.
My aims were 1) to establish the response of PBSC,
measured by the CFU-GM assay, to standard chemotherapy
regimes with particular reference to patients with
lymphoma, 2) to assess the ability to harvest these
progenitors by leukapheresis when numbers were raised and
3) to determine tumour infiltration in PBSC harvests
using gene rearrangement studies.
Circulating CFU-GM were studied sequentially in 64
patients (40 female, 24 male), 24 NHL, 22 HD, 9 AML, 5
ALL and 4 myeloma. Three patients with NHL receiving
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ALL type therapy showed a mean increase in CFU-GM 15.6
fold over normal values occurring on day 21. Eighteen
received CHOP based regimes and demonstrated a 6.2 fold
rise between days 15-28. PEEC increased progenitors in 2
patients 43 fold however CVP and VAD only raised CFU-GM
by 2.9 and 2.4 fold respectively. In those patients with
HD a 14.5 fold increase in PBSC was induced in the 4
patients treated with HOPE. ABVD and MOPP raised peak
values to 2.8 and 3.5 times normal and ChlVPP produced a
2.9 fold increase. In the lymphoma group as a whole,
standard chemotherapy failed to mobilise PBSC in 15% of
patients. Significantly lower peak CFU-GM were found in
patients who had received previous chemotherapy or who
had marrow involvement with disease.
Four patients with ALL were treated with UKALLX protocol.
Induction therapy induced a 5.3 fold rise in CFU-GM
occurring on day 21, however intensification produced
considerably greater increases to 35 times normal. High
dose Ara-C in 1 patient increased PBSC 16.8 fold. Of the
9 with AML 5 received DAT resulting in a mean CFU-GM peak
of 6336/ml (38 fold rise). The four remaining patients
treated with ADE increased PBSC 12.5 fold. VAD for
treatment of myeloma increased PBSC only 1.1 fold.
Standard chemotherapy failed to mobilise PBSC in 15% of
patients with acute leukaemia and in 75% of those with
myeloma.
Having established the timing of PBSC increases, 74 stem
cell harvests from 25 patients (8 NHL, 8 HD, 5 AML, 3
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ALL, 1 myeloma) were performed using a Fenwall CS3000
cell separator. In patients with lymphoma the mean yield
was 0.99 x 10^MNC/kg per procedure with 2.93 x lO^CFU-
GM/kg. In patients with acute leukaemia 1.2 x 10^MNC/kg
with 8.6 x 10^CFU-GM/kg per procedure were harvested. The
cells were cryopreserved.
Tumour contamination of PBSC harvests was investigated by
gene rearrangement studies with probes to IgHJ and TCR
f3 and 6 chains. Tumours from 22 patients (3 AML, 4 ALL, 7
NHL, 7 HD and 1 myeloma) and from 60 PBSC harvests were
analysed. Rearranged bands were detected in tumour from
10 patients but in none of the PBSC harvests.
In conclusion, standard chemotherapy for lymphoma and
leukaemia induced a rise in PBSC in the majority of
patients. These progenitors were harvested by
leukapheresis in sufficient numbers to allow engraftment.
Using gene rearrangement studies, the harvests appeared
free of tumour contamination.
The abbreviations for the chemotherapeutic regimes are




Autologous BMT is increasingly used in the treatment of
haematological malignancies and solid tumours. The dose
of many chemotherapeutic agents and of total body
radiotherapy that can be given to treat a large number of
tumours is limited by myelosuppression. For sensitive
tumours which exhibit a dose-response curve, the
probability of eradicating the disease is increased if
more intensive treatment is given. Transplantation of
stem cells, predominantly from the bone marrow, after
high dose therapy is capable of restoring marrow
function and thus overcoming the dose limiting effect of
myelotoxicity.
1.1. Haematopoietic stem cells
Haematopoietic stem cells have the capacity for self
renewal, proliferation and production of progenitors
committed by differentiation to the various blood cell
lines and therefore are able to permanently support
haematopoiesis. The rarity of the most primitive stem
cell has led to problems of identification so that
studies have required the development of functional
assays. Initially the spleen colony assay was devised
whereby marrow cells injected into irradiated mice led to
the formation of nodules in the spleen. These nodules are
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derived from single cells called CFU-S and were shown to
consist of differentiating cells of several haematopoietic
lineages (Till and McCulloch, 1968). CFU-S are capable of
self renewal and differentiation, demonstrated by re¬
injecting nodules into irradiated mice which subsequently
developed splenic colonies. However, CFU-S proved to be
heterogeneous in their ability to generate cells capable
of long term haematopoiesis and, as was shown recently,
many are distinct from the stem cells responsible for its
long term maintenance (Jones et al, 1990).
The development of in vitro semi-solid culture methods
for quantitation of haematopoietic progenitors has
allowed the detection of colonies derived from the
committed stem cell which generates the
granulocyte/monocyte lineage (CFU-GM or CFU-C) (Bradley
and Metcalf, 1966). These are not the equivalent to the
CFU-S in mice, but represent an intermediate population
between pluripotent stem cells and morphologically
recognisable myeloid cells (Wu et al, 1968). The number
of CFU-GM was shown to correlate with complete
restoration of haematopoiesis after bone marrow
transplantation in dogs (Abrams et al, 1981), but in man
the results were more variable. CFU-GM correlated with
neutrophil recovery but to a lesser degree with platelet
recovery (Spitzer et al, 1980). At present CFU-GM is the
most generally used predictor of haematopoietic
reconstitutive capacity.
Like CFU-S, however, CFU-GM is heterogeneous in its
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composition. Monoclonal antibodies against
lymphomonocytic and granulocytic surface antigens show 2
types of progenitor cells at different stages of
maturation and which are present in different proportions
in blood and bone marrow. CFU-GM in peripheral blood are
composed almost entirely of a more immature progenitor
which differentiates into a second form of CFU-GM found
predominantly in the marrow (Ferrero et al, 1983).
Attempts to further identify stem cells in man by
methods other than by cell culture, have employed flow
cytometry. Flow cytometric analysis has demonstrated
the number of cells expressing the antigen CD34 (CD34+
cells) present in the peripheral blood after stem cell
mobilisation correlated with CFU-GM from culture
experiments (Siena et al, 1991; Serke et al, 1991).
Subpopulations of CD34+ cells have been demonstrated and
the best predictor early haematopoietic recovery after
PBSCT found to be the number of cells that co-expressed
the antigen CD33 (CD34+/CD33+) (Siena et al, 1991). Cells
with phenotype CD34+/CD33- may be responsible for the
later sustained engraftment phase and contain the most
primitive haematopoietic cells. This hypothesis was
supported by recent evidence that cells from marrow
that were CD34+ but negative for T, B and myeloid cell
antigens have generated multiple colony forming cell
progeny (Andrews et al, 1990). Thus the positive
identification of the true human stem cell is coming
closer.
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1.2. The role of transplantation in haematological
malignancies
1.2.1. Lymphoma
In patients with NHL, more than 50% will relapse after
conventional chemotherapy and less than 10% of such
patients are cured (Cabanillas et al, 1982; Velasquez et
al, 1988). Dose escalation, as achieved by autologous
transplantation, produced a complete response in 14% of
patients with aggressive NHL resistant to standard
treatment after a follow up of 3 years (Philip et al,
1987). There are no direct prospective comparisons in NHL
between allogeneic and autologous BMT but comparing the
few reports of allogeneic with those of autologous BMT
there is no advantage in survival or frequency of relapse
in either procedure (Armitage, 1989). In a review of over
500 patients with intermediate and high grade NHL, the
best results of autologous transplantation were in those
with minimal tumour, early in the course of disease
(complete response or sensitive relapse) where 50% were
alive and well with follow up from 1 to 75 months
(Armitage 1989). The optimal timing of BMT in NHL is not
yet established, but if poor prognostic factors such as a
slow response to treatment (Armitage et al, 1986) can be
identified it may have a role in first remission.
In HD the situation is more complex with two thirds of
patients cured by local radiotherapy or chemotherapy
(Selby et al, 1987). A group with a poor prognosis can be
identified and includes those who do not completely
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respond to initial treatment or who do not respond to
second line therapy after relapse. BMT has been used
mainly for advanced cases of HD and even in these cases,
a 50% complete response rate was seen (Gribben et al,
1989; Armitage, 1989).
1.2.2. Acute leukaemia
For those patients with AML conventional chemotherapy has
improved over the last 20 years and now produces
remission in 76% of adults below 50 years of age (Rees et
al, 1986), with an overall LFS of 25 - 40% at 3 years
(Butturini and Gale, 1989). Allogeneic BMT is an
effective treatment with 48% LFS at 5 years for those
transplanted in first remission (Advisory Committee of
the International Bone Marrow Transplant Registry, 1989).
The role of autologous BMT in AML is less well defined
and is under prospective evaluation in the MRC AML X
trial. Other non-controlled studies have suggested a 36%
LFS at 7 years with autologous transplantation and after
in vitro chemotherapeutic marrow purging the European
BMT group have reported LFS of 60% at 5 years (Gorin et
al, 1989).
Modern chemotherapy regimes can cure approximately one
third of adults with ALL (Hoelzer and Gale, 1987),
whereas allogeneic BMT in first remission produces a LFS
of 40%. In second remission the LFS after BMT is 20%
compared with 5% after reinduction chemotherapy
(Butturini and Gale, 1989). Therefore BMT is appropriate
in first remission ALL only for those with poor
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prognostic features such as a high presenting white cell
count or a slow response to induction chemotherapy
(Hoelzer et al, 1988), and in second remission for those
with standard risk disease. As the numbers of adults with
ALL is relatively small, the role of autologous
transplantation has still to be established and the use
of marrow purging with chemotherapy or specific
monoclonal antibodies evaluated. The European BMT group
report a LFS of 41% at 3 years in poor prognosis ALL
after autologous transplantation in first complete
remission, but in only 10% during second remission (Gorin
et al, 1989).
1.3. Complications of BMT
BMT is a major procedure with an overall mortality of 20-
50% (Champlin and Gale, 1984). One of the main limiting
factors in allogeneic BMT is the availability of a
suitable donor. A patient has a 1 in 4 chance of having
an HLA identical sibling, but the size of western fami¬
lies means that such a donor is available for about 1/3
of patients (Black, 1982). Even with an appropriate
donor, GVHD occurs with a mortality of 30% in moderate to
severe cases (Storb et al, 1983). The use of autologous
marrow overcomes the problem of stem cell rescue and
removes the risk of GVHD, but the complications of marrow
hypoplasia such as bleeding and infection, which is re
sponsible for 10-20% of mortality in some reports, re¬
mains. The disadvantages of autologous BMT lie with the
potential for disease relapse. Tumour cells may be rein-
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fused with the marrow, but quantification of this risk is
impossible in view of the relatively insensitive assays
for tumour contamination in either the patient or graft.
The loss of the benefit of the graft versus leukaemia
effect of allogeneic marrow (Sosman and Sondel, 1991) may
make relapse more likely.
1.4. Peripheral Blood Stem Cells
The peripheral blood represents an alternative source of
stem cells to bone marrow. Progenitor cells are present
in the mononuclear cell fraction of peripheral blood in
both animals and man, and could be used to potentially
increase the use of autologous transplantation.
1.4.1. PBSC in animals
That buffy coat cells could protect irradiated parabiotic
mice from bone marrow failure was first documented in
1951 (Brecher and Cronkite, 1951). Using transplantation
experiments it was shown that in mice given blood-derived
white cell transplants, granulocytes and erythroblasts
were of donor origin and chimeras were established for
several months (Goodman and Hodgson, 1962). At an early
stage, the importance of the dose of transfused white
cells was shown in dogs (Cavins et al, 1964), when 10
times more peripheral blood was required to give haemato-
logical recovery compared with that of bone marrow.
When the properties of circulating haematopoietic stem
cells were compared to the known marrow derived stem
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cells, they were found to differ by having a lower
radiosensitivity, more cells in S phase and a higher
seeding efficiency (Gidali et al, 1974). Micklem and his
colleagues found the se1f-renewing capacity of
peripheral blood CFU-S was less than those in the marrow
(Micklem et al, 1975) and it was considered that they
represented a more committed fraction of the stem cell
population.
Development of the CFU-C assay, in which murine
haematopoietic cells could form granulocyte and monocyte
colonies in semisolid medium supplemented with growth
factors (Bradley and Metcalf, 1966), enhanced the study
of stem cells. CFU-C were found to be a good predictor of
engraftment of peripheral MNC (Northdurft et al, 1977)
and the importance of dose was becoming apparent. In dog
experiments a nucleated cell count of more than 3 x
10^/kg and CFU-C of 1.9 - 9.9 x 10^/kg resulted in
sustained engraftment for up to 3 years.
Harvesting of progenitors was facilitated in dogs by
treatment with cyclophosphamide to increase the
circulating pool of CFU-C (Abrams et al, 1981). This not
only increased the CFU-C 11 fold but also increased
haematopoietic recovery 12.5 fold after transplantation.
These encouraging results in animal experiments led on to
work in the human situation.
1.4.2. PBSC in man
Cells capable of forming colonies are present in the
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peripheral blood of man. This was first demonstrated by
Chervenick and Boggs in 1971 who observed colonies
containing granulocytes and monocytes in the feeder
layers of marrow cultures made from blood leukocytes
(Chervenick and Boggs, 1971). At the same time Kurnicke
cultured peripheral blood cells from patients with
infectious mononucleosis and other viral illnesses with
an increased number of circulating large lymphocytes and
found a greater number of granulocytic colonies than in
his normal population (Kurnick and Robinson, 1971). By a
series of depletion and separation experiments Barr
showed the stem cell activity which produced granulocyte
and erythroid colonies was found in a population of large
lymphocytes (Barr et al, 1975). Erythroid and
granulocytic colonies in peripheral blood, bone marrow
and cord blood were also observed (Fausner and Mesner,
1978) .
1.5. Stem Cell Mobilisation
Several factors were shown to mobilise PBSC. CFU-C were
increased four fold by exercise, two fold by ACTH
induced stress (Barrett et al, 1978) and hydrocortisone
(Morra et al, 1981), and four fold by endotoxin (Cline
and Golde, 1977). In certain disease states,
particularly myeloproliferative disorders such as
myelofibrosis and CML greatly increased numbers of
circulating progenitors were found (Chervenick, 1973;
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Hibben et al, 1984; Partanen, et al, 1982). The effects
of chemotherapy were first demonstrated by Richman in
1 9 7 6 who reported up to a twenty fold rise in
circulating CFU-C after intermittent chemotherapy for
solid tumours. She postulated it would be possible in man
to obtain a dose of stem cells with a small number of
leukaphereses, equivalent to a bone marrow harvest at the
time of CFU-C expansion (Richman et al, 1976).
The response of circulating stem cells in AML measured
by the CFU-GM assay was initially reported by To (To et
al, 1984). He found, in those patients who entered
remission, a twenty five fold increase in CFU-GM over
normal subjects occurred, which coincided with the
platelet count recovery. A mean of 11 x 10^ CFU-GM/kg
were harvested by leucapheresis and cryopreserved without
loss of viability. Similar increases in PBSC were
reported predominantly in AML but also in a small number
of patients with ALL (Bernard et al, 1985; Reid et al,
1989). Recently the administration of very high doses of
chemotherapy specifically to mobilise PBSC, was reported
with increased progenitors found in 69% of patients.
However, this was associated with significant morbidity
and even mortality (To et al, 1990).
During very early remission in AML, the ratio of the
more primitive pluripotent cell, CFU-mix, to CFU-GM was
reported to be increased (Geissler et al, 1986). However,
this was not confirmed by others (Juttner et al, 1986;
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Reid et al, 1989) and thus the predictive capacity of
CFU-mix for engraftment remains unclear. This also
applies to bone marrow transplantation where in vitro
treatment of marrow with 4-hydroperoxycyclophosphamide
destroyed CFU-mix without loss of transplantation
potential (Rowley et al, 1985).
1.6. PBSC Autografting
1.6.1. Early studies
Transplantation experiments in animal models showed it
was feasible to obtain adequate numbers of stem cells
from the peripheral blood by leukapheresis to allow
reconstitution of haematopoiesis (Debelak-Fehir et al,
1975; Cavins et al, 1964; Northdurft et al, 1977),
particularly if the stem cell pool was expanded, for
example, by dextran sulphate or cyclophosphamide
(Gerhartz et al, 1985; Abrams et al, 1981). In man it
became apparent that blood contained cells capable of
establishing haematopoiesis when some neutropenic
patients treated with buffy coats from patients with CML,
transiently developed Ph' positive haematopoiesis
(Freireich et al, 1964). However, the first use of PBSC
for autografting in man was in CML where cryopreserved
buffy coat cells from patients with chronic phase disease
were used to restore haematopoiesis after ablative
therapy for accelerated phase or blast crises. (Goldman
et al, 1979). Marrow function was rapidly restored but
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relapse inevitably occurred. Normal stem cells from a
chemotherapeutically induced Ph' negative phase of CML
were also transplanted by Korbling with complete
haematopoietic Ph' negative reconstitution in the short
term (Korbling et al, 1981). Ph' negative haematopoiesis
was also restored by transplantation of CML buffy coat
cells grown in liquid culture in vitro to allow
preferential expansion of the normal stem cell over those
belonging to the malignant clone (Marcus and Goldman,
1986).
Early attempts at grafting using PBSC derived from
identical twins were unsuccessful, probably due to low
CFU-GM dose and long periods of reinfusion. The first was
performed for marrow aplasia in a patient with paroxysmal
nocturnal haemaglobinuria who received 3.4 x 10^ CFU-
GM/kg over a 2 week period with no conditoning but failed
to engraft (Hershko et al, 1979). The second patient had
a Ewing's sarcoma and after conditioning, received 0.9 x
10^CFU-GM/kg obtained by 8 leukaphereses from his sibling
The cells were reinfused over several days but did not
result in an acceleration of granulocyte, monocyte or
platelet recovery (Abrams et al, 1980).
1.6.2. PBSCT in leukaemia
The reconstitutive ability of PBSC in leukaemia has been
established but the therapeutic effects of PBSCT are not
yet clear. Initial case reports on the use of PBSCT in 2
patients with relapsed AML showed early engraftment and
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early relapse (Juttner et al, 1985). A further patient,
however, remained in remission for at least 7 months with
sustained haematopoiesis (To et al, 1987a). Various other
case studies differed, suggesting that in first and
second remission, response could be either sustained or
that early relapse may occur (Reiffers et al, 1988; Bell
et al, 1988). In a relatively large study of 26
patients transplanted in first complete remission,
Reiffers estimated a DFS at 3 years of 33%, which is
similar to that of autologous bone marrow
transplantation. These 2 procedures are being
prospectively compared (Reiffers et al, 1990).
Even fewer PBSCT for ALL have been reported, but 2 case
studies found good engraftment with remission continuing
up to 6 months (Bell et al, 1987b; Tilly et al, 1986).
1.6.3. PBSCT in lymphoma
PBSC may also be of benefit in the treatment of patients
with lymphoma. A 25% 2 year DFS was reported after PBSC
transplant for malignant lymphoma in dogs, this was
similar to results obtained after BMT (Appelbaum et al,
1986). The first human with lymphoma to undergo PBSCT was
a patient with Burkitt's lymphoma who was treated with
high dose chemoradiotherapy followed by reinfusion of
PBSC. The patient remained well during the 7 months
follow up period (Korbling, et al, 1986).
Kessinger has reported the results of PBSC
transplantation in the largest series of patients with
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lymphoma. Sixteen patients with NHL and 24 with HD were
studied. All had refractory disease and had received much
previous therapy. Many had marrow involvement or had
received pelvic radiotherapy. The clinical response
compared well with autologous BMT with a 2 year EFS of
49% for those with NHL and an 18 month EFS of 15% in HD
(Kessinger et al, 1989a).
1.6.4. PBSCT in Myeloma
In one study, PBSCT in myeloma produced considerable
tumour reduction in 87% and a complete response in 25% of
8 patients with stage III aggressive disease (Fermand et
al, 1989). When used as early intensive treatment a
similar response was found, with 25% remaining in CR at 5
and 14 months (Bell et al, 1990). The long term results
and role of this mode of therapy still have to be
established.
Stem cells in the peripheral blood can be harvested and
successfully establish haematopoiesis. In the small
numbers of patients studied, the results of PBSC
transplantation compare favourably to those found after
BMT and thus this form of treatment deserves further
study.
1-7. Advantages of PBSC
1.7.1. Collection of PBSC
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The advantages that PBSC have over bone marrow are that
they can be harvested without the prerequisite of a
healthy pelvic bone marrow and without the need for a
general anaesthetic, therefore if a patient has marrow
fibrosis as a result of previous radiotherapy or marrow
infiltration, this therapeutic option is still available.
As the stem cell activity is found in the lymphocyte
fraction of peripheral blood, leukapheresis is used to
harvest progenitors. Many cell separators employing
continuous and discontinuous flow have been used
successfully such as the Aminco centrifuge (Korbling et
al, 1980), the Hemonetics Model V50 (Schouten et al,
1990), the Cobe Spectra (Hillyer et al, 1990) and the
Fenwall CS3000 (Lasky et al, 1982). The more recent
protocols and use of separators with computer control
have increased efficiency and ease of the procedure (To
et al, 1989). After collection, harvests have been
cryopreserved with or without further manipulation,
mainly using 10% by volume of DMSO as cryoprotectant and
freezing using a controlled rate freezer before being
stored in liquid nitrogen (Korbling et al, 1988). The
products of several leukapheresis procedures are
generally reinfused at transplant, therefore purification
of stem cells to avoid side effects from the infusion of
large amounts of DMSO and contaminating red cells
(Kessinger et al, 1990) and to eliminate post-thaw
granulocyte clumping, may be performed. Density gradient
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separation of the product manually or by machine
(Hillyer et al, 1990; Law et al, 1988) will inevitably
result in the loss of some cells but Douay has suggested
that without Ficoll separation there is a significant
loss of CFU-GM after cryopreservation (Douay et al,
1989) .
1.7.2. Rapid haematopoietic reconstitution
The observation that haematopoietic reconstitution is
rapid after PBSCT offers the advantage of a shorter
period of neutropenia, the potential for a lower
infection rate and subsequent mortality. Rapid
reconstitution is seen in those patients transplanted
with PBSC collected after mobilisation by chemotherapy
(Korbling and Martin, 1988) but recovery rates similar
to autologous marrow transplantation occur when
progenitors are collected during steady state
haematopoiesis (Kessinger et al, 1988).
1.7.3. Lower tumour contamination
A further potential advantage of PBSC is the possibility
of lower levels of tumour contamination than in bone
marrow. If this were the case it may prevent some
relapses after transplantation. It is well recognised
that relapse is also due to residual disease in the
recipient therefore conditioning regimes also need to be
improved. One report suggesting that PBSC may have less
tumour contamination was that of To who employed
morphological and cytogenetic techniques to examine a
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harvest from a patient who had AML with the blast cells
containing Auer rods and a specific chromosomal
translocation. No leukaemic blasts were found in the PBSC
harvest using these techniques the sensitivity of which
was 2% (To et al, 1987b). Bell compared IgHJ gene
rearrangements in PBSCH with bone marrow from patients
after treatment for myeloma and found the incidence of
tumour contamination was less (Bell et al, 1990).
1.8. Disadvantages of PBSC
1.8.1. CFU-GM dose
Juttner reported the initial experience in AML involving
2 patients with relapsed disease who received 29 and 23
x 10^ CFU-GM/kg and both demonstrated initial
haematopoietic reconstitution. However, one relapsed and
died at day 11 and the other showed a secondary fall in
blood counts which remained persistently low after day 16
until the patient relapsed (Juttner et al, 1985). When
higher doses of CFU-GM (230 x 10^/kg) were given to
another patient, normal blood counts were reached by day
14 and did not fall thereafter. After further experience
this group concluded that rapid and complete engraftment
in AML required doses of CFU-GM greater than 63 x 10^/kg
(To et al, 1986). Other workers confirmed rapid and
sustained recovery of counts although CFU-GM doses
varied, eg Henon reported neutrophils >0.5 x 10^/1 at 10
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days and platelets > 50 x 10/1 at 18 days in patients
receiving 39 x 10^CFU-GM/kg (Henon et al, 1988).
In non-leukaemic patients the dose of stem cells required
for engraftment is also variable, but appears to be less
than in patients with AML . The first patient with
lymphoma to undergo PBSCT received 21 x 10^ CFU-GM/kg
collected in 7 leukaphereses after chemotherapy and
cryopreserved (Korbling and Martin, 1988). He showed
rapid haematopoietic reconstitution with neutrophils >0.5
xlO^/1 and platelets > 50 x 10^/1 both on day 10. Of 2
patients with NHL who received PBSC collected after
chemotherapy, one, transplanted with 60 x 10^ CFU-GM/kg
showed a rapid and complete haematopoietic
reconstitution, but the second patient, given a smaller
dose (33 x 10^CFU-GM/kg), died on day 21 with severe
hypoplasia (Bell et al, 1987b). Stiff noticed incomplete
platelet reconstitution in patients with lung tumours
transplanted with a mean of 11.4 ± 9.9 x 10^ CFU-GM/kg
(Stiff et al, 1987), whereas Lasky infused 1.1 - 5.7 x
10^ CFU-GM/kg to 7 patients with HD and reported
sustained engraftment (Lasky et al, 1989). Korbling
transplanted 3 patients with lymphoma who received PBSC
mobilised after chemotherapy and found rapid and complete
recovery when 6.5 x 10^ CFU-GM/kg were infused, but an
incomplete platelet response if the patients received < 2
x 10^/kg . (Korbling and Martin, 1988).
PBSC have also been harvested under steady state
conditions and transplanted but reconstitution has been
18
no faster than with bone marrow (Williams et al, 1990;
Phillips et al, 1990). In Kessinger's series of lymphoma
patients a mean of 8 PBSC collections during steady state
O
haematopoiesis were performed harvesting 7 x 10 MNC/kg
with 0.6 x 10^CFU-GM/kg. Engraftment was similar to that
found in bone marrow transplants taking 25 days to
Q
increase neutrophils to over 0.5 x 10^/1 (Kessmger et
al, 1989).
1.8.2. PBSC mobilisation and prediction of flux
The nature of the CFU-GM assay requiring a 2 week
incubation period makes it impossible to give a rapid
result and thus provide a clinically useful indication as
to when levels of circulating CFU-GM are high and
suitable for harvesting. Indirect measurements of the
appearance of PBSC such as the synchronous recovery of
monocytes and platelets in patients with AML (Reid et al,
1989), or a rapid rise in white cell count (Cantin et al,
1989) have been used. In order to specifically mobilise
stem cells, high dose chemotherapy such as
cyclophosphamide (4g/m ) were given. This mobilised high
numbers of CFU-GM at predictable times in 69% of patients
but with considerable morbidity and one death (To et al,
1990). The recent demonstration of immunophenotypic
methods for CD34 estimations which correlate with stem
cells may overcome this to some extent.
1.8.3. Quality of PBSC
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The quality of PBSC in comparison to bone marrow
progenitors and their ability to maintain long-term
haematopoiesis has also been questioned predominantly
based on results from mouse experiments (Micklem et al,
1975). Successful long term reconstitution has, however,
been demonstrated in dogs (Northdurft et al, 1977) and in
several studies in man (Reiffers et al, 1990; Kessinger
et al, 1989).
In this study, variations in the levels of PBSC were
examined, using the CFU-GM assay, in patients with
haematological malignancies to determine the effects of
standard chemotherapy regimes on their levels at various
time intervals. Having established the timing of PBSC
flux after standard chemotherapy, the feasability of
collecting progenitors was assessed by performing PBSC
harvests using a CS3000 cell separator. Finally, the
degree of tumour contamination in the harvests was
investigated by gene rearrangement studies.
1.9. Tumour contamination of PBSCH
The presence of tumour cells in PBSCH may be an important
source of disease from which relapse could occur.
Differentiating tumour from stem cells and other
mononuclear cells in the harvest can be attempted by
various methods such as light microscopy, cytogenetic
studies, and immunophenotypic analysis. All these
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systems depend upon the recognition of a tumour marker.
1.9.1. Immunological genes
DNA analysis of Ig and TCR genes has proved a useful tool
for the detection of residual disease in some
haematological malignancies. Antibody molecules are
proteins made from two heavy chains and two light
chains. Antigen binding sites on antibody molecules
consist of a cleft composed of two side walls. Each wall
is made of three polypeptide loops from either a heavy
chain variable region or a light chain variable region.
Diversity of the shape of the cleft results from
differences in the amino acid sequence of these heavy and
light chain variable regions. Amino acid variability is
achieved by recombination of encoding DNA sequences.
(Tonegawa, 1983). During early B cell development
segments of DNA from IgH variable, diversity and joining
regions, situated on chromosome 14, are brought together
by DNA recombination and this rearranged sequence is
transcribed into RNA (fig 1.1). The light chain gene V
and J segments from chromosome 22 recombine in a similar
manner. The vast numbers of different combinations
generate the large repertoire of antibody molecules
(Tonegawa, 1983). Further variability is introduced by
the imprecise nature of the V-D-J fusion and the non
specific addition of nucleotides at recombination. As the
DNA nucleotide sequence must be aligned correctly for
translation of an in-frame amino acid sequence, during
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recombination stop codons tend to be generated resulting
in a non productive rearrangement. If this happens, the
process is repeated using the second allele in order to
produce a functional antibody.
The T cell receptor protein consists of a//3 chains in the
vast majority of mature T cells, or in a minority, of
r/6 chain combinations found predominantly on CD4-/CD8-
cells (Knowles, 1989). The V, D and J segments which
encode the Variable TCR regions, recombine in a similar
fashion to IgH V-D-J segment rearrangements.
The repertoire of B and T cells consists of very large
numbers of immune lymphocytes, each with different V-D-J
rearrangements of either IgH and light chains or TCR a//3
or r/6 chains. These gene sequence rearrangements may be
analysed by restriction enzyme cleavage, agarose gel
electrophoresis to separate fragments of DNA by size,
Southern blotting and hybridisation with a DNA probe
complementary to part of the rearranged sequence. In the
normal immune cell repertoire, gene rearrangement studies
identify one or two bands due to unrearranged germline
alleles and a smear generated by the large number of
cells with different V-D-J rearrangements. However, in
the case of neoplastic transformation, there is clonal
expansion of a single malignant lymphocyte containing a
specific V-D-J segment which can be detected by gene
rearrangement studies as a single band (Rabbitts, 1986).
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Immunoglobulin heavy chain gene recombination. During B
cell development, antibody diversity is created by the
recombination of any one variable (V) segment with any
one diversity (D) segment and any one joining (J) segment
of DNA to produce a functional V-D-J gene. This is then
transcribed into mRNA and translated into IgH protein.
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Gene rearrangement studies have proved useful in
assigning lineage to lymphoid tumours, but in
approximately 15% of patients reported, both TCR and IgH
genes are rearranged. (Pellici et al, 1985; Tawa et al,
1985; O'Connor et al, 1987; Seremetis et al, 1987). In
NHL, IgHJ gene rearrangements were found in all tumours
of B cell origin in 2 reported series (Aisenberg et al,
1987; Williams et al, 1987) and TCR/3 gene rearrangements
in 96% of T cell NHL (Williams et al, 1987; Griesser et
al, 1986) . In HD the cell of origin is still
controversial and most tumours do not demonstrate gene
rearrangements. An average of 9% of 117 patients from 7
reported series showed IgHJ gene rearrangements, 9% TCR/3
gene rearrangements and 28% of 7 patients TCR 6 gene
rearrangements. (Greissler et al, 1986; Brinkler et al,
1987; Sundeen et al, 1987; O'Connor et al, 1987; Henni et
al, 1988; Tkachuk et al, 1988; Gledhill et al, 1990).
An average of 7% of 204 patients with AML from 5 reported
series showed IgHJ and 14% TCR /3 gene rearrangements
(Cheng et al, 1986; Seremitis et al, 1987; Ackland et
al, 1987; Foroni et al, 1989; Dyer et al, 1988). TCR 6
gene rearrangements have been reported in 32% of 65
patients with AML from 3 studies (Foroni et al, 1989;
Dyer et al, 1988; Asou et al, 1989). In those patients
with B cell lineage ALL almost all had IgHJ rearranged
(Korsameyer et al, 1983) and in 5 reported series of 50
patients with T cell lineage ALL, 92% demonstrated TCR/3
rearrangements (Pellici et al, 1985; Waldemann et al,
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1985; Knowles et al, 1986; Felix et al, 1987; O'Connor
et al, 1987 ) .
Circulating clones of cells detected by gene
rearrangement studies have been found in 38% of untreated
or relapsed patients with NHL, most commonly in advanced
disease and low grade disease (Brada et al, 1987). A
similar result was seen by Horning who found 34% positive
with low grade NHL and only 8 % in intermediate disease.
When patients were clinically free of disease
irrespective of grade, DNA analysis of peripheral blood
was still positive in 10% (Horning et al, 1990).
Gene rearrangement studies have provided tumour markers
in the majority of patients with acute leukaemia and NHL
and in some with HD and AML. This approach was used to
investigate tumour contamination of peripheral blood stem
cell harvests.
1.10. AIMS
The aims of this project were as follows:
To investigate the response of PBSC to standard
chemotherapy used in the treatment of haematological
malignancies and to determine the pattern of variation in
numbers.
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To investigate the feasibilty of collection of these
progenitor cells after standard chemotherapy.




PERIPHERAL BLOOD STEM CELLS
The response of peripheral blood stem cells to standard
chemotherapy regimes for the treatment of haematological
malignancies was investigated.
2.1. Materials
Ficoll-hypaque 1.077g/ml (Pharmacia, Uppsala, Sweden)
FCS (Northumbria Biological), heat inactivated at 56°C
for 30 min to destroy complement
Gentamicin (Sigma, Poole,Dorset, UK.)
HBSS (Northumbria Biological)
IMDM (Gibco/BRL, Paisley, UK)
2 mercaptoethanol (Sigma)
Methylcellulose 4000 cps (Sigma)
Penicillin and streptomycin solution (Northumbria
Biological, Cramlington, Northumbria, UK.)
PHA (Wellcome Diagnostics, Dartford, UK)
Preservative free heparin (Leo Laboratories, Princes,
Risborough UK)
All plastic-ware was from Costar, Massachusettes
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2.2. Subjects and patients
2.2.1. Normals
To establish normal values for PBSC, CFU-GM from 43
healthy volunteers (19 male, 24 female, mean age 30.3
years, range 15 - 57) were assayed throughout the study
period.
2.2.2. Patients
Circulating CFU-GM were measured on serial blood samples
from 64 patients with haematological malignancies (Table
2.1) undergoing standard chemotherapy. AML was classified
according to the FAB criteria (Bennett et al, 1985), ALL
according to MIC criterea (First MIC Cooperative Study
group, 1986) , and NHL according to the Keil
classification (Stansfield et al, 1988). Patients with
lymphoma were clinically staged according to the Ann
Arbor system (Carbone et al, 1971). Bone marrow
involvement was assessed by light microscopic examination
of marrow aspirate and trephine biopsy.
Of the 24 patients with NHL, 21 had high grade, 3 low
grade disease, one stage I, one stage II, 7 stage III and
13 stage IV disease. In those with HD, 3 had stage I, 4
stage II, 4 stage III and 11 stage IV.
The FAB classification of AML gave 4 Ml, one M2, one M3,
2 M4 and one M5. The MIC classification of the patients

























Total 64 41.6 40M 11
(14-70) 24F
TABLE 2.1 Characteristics of patients receiving
chemotherapy
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The chemotherapy regimes used are described in tables
2.II to 2.V. Eighteen patients with NHL received CHOP-
based regimes (hereafter referred to as CHOP), 16 being
BCHOP-M as described in table 2.II, the other 2 omitting
bleomycin and methotrexate. Cycles were repeated every 21
days, counts permitting. CVP was given every 4 weeks and
VAD every 6 weeks.
Patients with HD received ChlVPP, ABVD, MOPP, HOPE and
OPEC every 4 weeks.
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9
BCHOP-M bleomycin 7.5mg/m iv, cyclophosphamide
9 9 • 9
750mg/mz iv, adriamycin 40mg/m iv, vincristine 1.4mg/m
iv all day 1, prednisolone 40mg po days 1-5,
methotrexate 200mg/m iv day 15 with oral folinic acid
rescue.
ALL daunorubicin 45mg/mziv days 1 & 2, vincristine
9 « 9
1.5mg/m iv days 1,8,15,22 & 29, prednisolone 40mg/m po
days 1-28, asparaginase 6000U/m sc 3/week x 9.
9
PEEC methylprednisolone 250mg iv, vindesine 3mg/m both
9 • 9
day 1, etoposide lOOmg/m iv day 1, 200mg/m po days 2 &
3, chlorambucil 20mg/m po days 1,2 & 3, methotrexate
9
200mg/m iv day 15 with oral folinic acid rescue.
CVP cyclophosphamide lg iv and vincristine 2mg iv day 1,
prednisolone 40mg po days 1-5.
9 • 9
VAD vincristine 0.4mg/m and adriamycin 9mg/m'i iv days 1-
4, dexamethasone 40mg daily po days 1-4, 9-12 and 17-21.
TABLE 2.II NHL Chemotherapy regimes
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• 9 9
ChlVPP chlorambucil 6mg/m po, procarbazine lOOmg/m po
and prednisolone 40mg po daily all days 1-14,
vinblastine 6mg/m iv days 1 & 8.
9 9
ABVD adriamycin 25mg/m iv, bleomycin lOmg/m iv,
9 9vinblastine 4mg/m iv and DTIC 375mg/m iv all days 1 &
15.
9 9
MOPP procarbazine lOOmg/m po, prednisolone 40mg/m po
both days 1-14, mustine 6mg/m iv and vincristine
1.4mg/m iv both days 1 & 8.
9 9
HOPE adriamycin 40mg/m iv day 1, vincristine 1.4mg/m iv
days 1 & 8, prednisolone lOOmg po days 1-8, etoposide
200mg/m po days 1-4, bleomycin 10 mg iv days 1 & 8.
OPEC chlorambucil 6mg/m po and prednisolone 40mg po
daily days 1-14, etoposide 200mg/m^ po days 1-5,
• 9 •
vincristine 1.4mg/m iv days 1 & 8.
TABLE 2.Ill HD chemotherapy regimes
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UKALL (INDUCTION) daunorubicin 45mg/m^ iv days 1 & 2,
vincristine 1.5mg/mz iv days 1,8,15,22 & 29, prednisolone
40mg/m po days 1-28, asparaginase 6000U/mz sc 3/week x
9.
UKALL (INTENSIFICATION) prednisolone 40mg/m^/day po days
1-7 stopping over 1 week, vincristine 1.5mg/m iv day 1,
9 9
daunorubicin 45mg/m iv days 1 & 2, etoposide 100mg/mz iv
days 1-5, cytosine arabinoside lOOmg/m bd iv days 1-5,
thioguanine 80mg/m po days 1-5
9
MACHO cyclophosphamide 300mg/m bd iv days 1-3,
9 9
vincristine 1.5mg/m iv days 4 & 11, adriamycin 50mg/m
iv day 4, methotrexate 2.5g/m iv day 15 with iv folinic
acid rescue, on recovery, ara-C 2g/m bd iv for 3 days
followed by methotrexate 2g/m iv 15 days later with iv
folinic acid rescue.
o
DAT 3+10 daunorubicin 50mg/mz iv days 1, 3 & 5, cytosine
arabinoside 100mg/mz iv bd days 1-10, thioguanine
100mg/m^ po days 1-10. Note DAT 1+5 has 1 day of
daunorubicin and 5 days of cytosine and 6TG.
ADE cytosine arabinoside 100mg/mz iv bd days 1-10,
daunorubicin 50mg/m^ iv days 1, 3 & 5, etoposide 100mg/m^
iv days 1-5.
TABLE 2.IV Acute leukaemia chemotherapy regimes
33
2-3 Methods
Sterile reagents, equipment and technique were employed
throughout cell culture work.
2.3.1. CFU-GM assay
PBSC were assessed in a semi solid culture system using
the CFU-GM progenitor assay based on a modification of
that of Fausner and Messner (1978). Twenty ml of periph¬
eral blood were collected into 300U of preservative free
heparin and then diluted 1:1 with HBSS. The light densi¬
ty MNC were isolated by density gradient centrifugation
over Ficoll-hypaque (1.077g/ml) at 400g for 30 min ac¬
cording to Boyum, 1964. The MNC were removed, washed
twice in HBSS + 2% FCS and resuspended in IMDM + 2% FCS.
Cells were plated at 4 x 10^/ml in IMDM with 1.44%
methy1ce11u1ose , 30% FCS, 10% PHA LCM, 250pg/ml
gentamicin, lOOu/ml penicillin and lOOpg/ml streptomycin.
Cultures were set up in duplicate in 22.6mm diameter
wells in 12 well tissue culture plates, incubated at 37°C
in a humidified atmosphere containing 5% CO2 for 14 days
and then colonies >40 cells were counted using an
inverted microscope.
2.3.2. Preparation of PHA LCM
From the same donor 20 ml peripheral blood were collected
into 300u preservative free heparin and the MNC isolated
by density gradient centrifugation over Ficoll-hypaque as
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described above. The MNC were washed twice in HBSS + 2%
FCS and resuspended in IMDM + 2% FCS to give a final
concentration of 1 x 10^ MNC/ml containing 1% PHA, 10%
FCS, 50/jM 2 mercaptoethanol and antibiotics (Gentamicin
250pg/ml, penicillin lOOu/ml and streptomycin lOOpg/ml)
in IMDM. This was incubated at 37°C in a humidified
atmosphere containing 5%CC>2 for 4 days when it was
decanted, centrifuged at 200g for 10 min and the
supernatant (PHA-LCM) filter sterilised and frozen at
-40°C. Each batch was discarded after 1 month.
2.3.3. Analysis of colony cell types
Colony type was verified periodically by transferring
colonies from the plates into 200pl cooled IMDM with 30%
FCS using an automatic pipette. The cells were gently
agitated and then transferred onto a glass slide by
cytocentrifugation (300g for 3 min). The slides were
allowed to air dry, fixed as appropriate, stained with
May Grunwald Geimsa or combined esterase (Naphthol AS-D
Chloroacetate and a-naphthol acetate) and examined under
the light microscope.
For May Grunwald Giemsa staining the slides were fixed in
methanol for 10 min, stained in 50% May Grunwald for
15 min, transferred to 10% Giemsa stain for 10
min and finally washed in buffered water before air
drying.
For combined esterase staining the slides were fixed in
phosphate buffered acetone formaldehyde at 6°C for one
35
minute, stained with a phosphate buffered solution
containing ethylene glycol monomethyl ether (1/25
vol/vol), 20mg a-naphthol acetate and 15mg fast garnet
GBC for 30 min at room temperature, washed and
transferred to phosphate buffered solution containing the
filtered products of N,N dimethylformamide mixed with
naphthol AS-D chloroacetate and fast blue BB for a
further 30 min before being washed and counterstained
with Harris haematoxylin for 5 min and air dried.
2.3.4. Expression of CFU-GM results
CFU-GM were expressed per ml of blood. This value was
obtained by comparing the numbers of colonies obtained
for a known MNC plating number with the total MNC
count/ml obtained from a full blood count sample taken at
the same time.
2.3.5. Blood cell counting
Platelets and white cells were counted by a Sysmex NE8000
(LEP Scientific) automated cell counter. Where required
visual 100 cell differential white cell counts were
performed.
2.3.6. Statistics
Comparisons were made using the student's t-test on
square root transformed data.
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2.4 Results
2.4.1 Morphology of CFU-GM colonies
The characteristic appearance of a CFU-GM colony is shown
in fig 2.1. After removal from the culture well and
staining, the granulocytic and monocytic elements can be
seen (fig 2.2 and 2.3).
2.4.2 Effect of MNC plating concentration
The effect of plating an increasing concentration of MNC
on CFU-GM colony numbers is shown in figure 2.4 and 2.5.
A linear increase in CFU-GM was found with MNC from
normal individuals and from PBSCH.
2.4.3. CFU-GM in a normal population
CFU-GM assays performed on the peripheral blood of 43
healthy volunteers resulted in a mean value of 166 CFU-
GM/ml, SEM 19. The data was normally distributed once
square root transformed. A group of 20 values obtained
near the beginning of the experimental period was not
significantly different from a group obtained towards the
end of the period (p = 0.38).
2.4.4. CFU-GM in patients with lymphoma
2.4.4.1. NHL
Patients with NHL received the chemotherapy regimes shown
in table 2. III.
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FIGURE 2-1 Photomicrograph of CFU-GM colony in situ in
culture well (x40)
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FIGURE 2.2 Photomicrograph of cytospin preparation of
cells from a CFU-GM colony stained with May Grunwald




FIGURE 2.3 Photomicrograph of cytospin preparation of
cells from a CFU-GM colony stained with combined esterase
and demonstrating the presence of both cell types.
Granules in the cytoplasm of cells of the monocyte
lineage stain brown whilst granules in the cytoplasm of
cells of the granulocyte lineage stain blue.
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FIGURE 2-4 The effect of increasing MNC plating
concentration on the absolute number of CFU-GM colonies






SCH 1 SCH 2
FIGURE 2.5 The effect of increasing MNC platin
concentration on the absolute number of CFU-GM colonie
from 2 stem cell harvests.
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Two patients were treated with BCHOP alternating with
PEEC whilst the others received only one regime.
The maximum levels of CFU-GM/ml blood throughout the
whole chemotherapy period irrespective of course number,
are shown in fig 2.6. CVP and VAD raised CFU-GM by 2.9
and 2.4 fold respectively, whereas PEEC produced wide
variations in values in the 2 patients studied. ALL
therapy induced a mean 15.6 fold increase in PBSC
occurring between days 20 - 22. In the 18 patients who
received CHOP based regimes the mean CFU-GM peak was
1026/ml representing a 6.2 fold rise over our normal mean
value and occurred on average at day 19 (range 15 - 29)
(table 2.V). In one patient, CFU-GM did not rise. An
example of the response of CFU-GM to BCHOPM chemotherapy
in a typical patient with NHL is shown in figure 2.7.
2.4.4.2. Hodgkin's Disease
Figure 2.8 shows the maximum circulating CFU-GM in 22
patients with HD treated with various chemotherapy re¬
gimes. Six patients received alternating regimes (5
MOPP/ABVD, one HOPE/ChlVPP) and one received both first
line and second line chemotherapy. No increase was found
in 45% of patients including 4 of 10 treated with ChlVPP,
2 of 5 after MOPP and 3 of 9 after ABVD. These regimes
produced a 2.8 - 3.5 fold increase in CFU-GM over normal
values. HOPE induced a mean 14.5 fold rise in all 4

















FIGURE 2.6 Peak levels of CFU-GM/ml in 24 patients with
NHL treated with various chemotherapy regimes. The mean
values obtained after each chemotherapy regime is shown
as a dotted line and the mean CFU-GM ± one SEM found in
our normal population represented in the hatched area.
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Mean Peak Mean day
Chemotherapy CFU-GM/ml of peak
Regime n (range) (range)
NHL CHOP 18 1026 19
160-4540 15-29
ALL 3 2595 21.3
2227-2906 20-22
PEEC 2 7181 18.5
768-13595 15-22
CVP 2 475 11
461-490 9-13
VAD 1 391 22





FIGURE 2.7 Response of CFU-GM (solid line) and white
blood count (wbc, dotted line) after 3 courses of BCHOPM
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HODGKIN'S DISEASE
FIGURE 2.8 Peak levels of circulating CFU-GM/ml in 22
patients with HD treated with various chemotherapy re¬
gimes. The mean values obtained for each chemotherapy
regime is shown as a dotted line and the mean CFU-GM ±
one SEM found in our normal population represented by the
hatched area.
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Mean Peak Mean day
Chemotherapy CFU—GM/ml of peak

















OPEC 1 238 30
Table 2.VI Response of CFU-GM to chemotherapy in patients
with HD
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2.4.4.3. Effect of marrow involvement
Nine patients (3 HD, 6 NHL) had bone marrow involvement
by disease detected by morphology and/or
immunophenotyping. CFU-GM increases (469/ml ± 76) were
significantly less (p = 0.017) in these patients when
compared to those with no evidence of marrow infiltration
(1319/ml ± 339) (fig 2.9). Of the 18 patients with NHL
treated with CHOP based regimes, 3 had bone marrow in¬
volvement with lymphoma. These 3 patients had signifi¬
cantly lower increases in CFU-GM (451/ml ± 21) compared
to those without marrow involvement (1141/ml ± 292; p =
0.024) .
2.4.4.4. Effect of second line chemotherapy
Eight patients (7 HD, 1 NHL) had relapsed disease and
were receiving second or subsequent line chemotherapy. A
significantly lower CFU-GM peak (295/ml ± 48 cf 1328/ml,
p = 0.0001) was found in those treated with second or
subsequent therapies (fig 2.10).
2.4.4.5. Effect of course number
In those patients with NHL receiving CHOP based regimes
on whom there was adequate data during chemotherapy, no
significant difference was found in the mean CFU-GM peak
















FIGURE 2.9 Peak levels of CFU-GM after chemotherapy in
patients with lymphoma with bone marrow involvement
compared to those without bone marrow involvement by
disease. Significantly lower peak CFU-GM/ml were found in
those patients with marrow involvement (Student's t-test
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chemotherapy chemotherapy
FIGURE 2.10 Peak levels of CFU-GM/ml in patients with
lymphoma in those receiving first line chemotherapy
compared with those receiving second or subsequent line
chemotherapy. Significantly lower levels of CFU-GM/ml
were found in those patients receiving second line or
subsequent line chemotherapy (Student's t-test on square
root transformed data, p = 0.0001).
Coarse Mean Peak Mean Day Comparison
Number n CFO—GM/ml of Peak to 1st. coarse
1 13 923 20.5
2 15 553 19.4 p = 0.34
3 7 204 21.6 p = 0.064
4 6 440 20.5 p = 0.26
TABLE 2.VII Effects of successive courses of CHOP
chemotherapy on CFU-GM peak.
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2.4.5. CFU-GM in acute leukaemia
2.4.5.1 AML
Figure 2.11. shows the peak circulating CFU-GM in 9
patients with AML treated with either DAT (5 patients) or
ADE (4 patients) chemotherapy. Three patients went on to
receive a second course of DAT and 2 a second course of
ADE. The mean CFU-GM peak in those treated with DAT was
6336/ml, a 38 fold rise over normals occurring on average
at day 28.6 (range 20 - 36). Those receiving ADE demon¬
strated a 12.5 fold increase to 2083 CFU-GM/ml on day 26
(range 23 -28) (Table 2.VIII). The response of CFU-GM to
ADE chemotherapy in a typical patient is shown in fig
2.12. One patient in each treatment group did not have a
rise in PBSC. Neither demonstrated a platelet count above
60, nor had they entered remission after this course of
treatment. There was no significant difference in the
levels of CFU-GM attained after the first or second
course of treatment in the small group of 5 patients as a
whole, however, when considered individually variations
in CFU-GM response were found Fig 2.13.
2.4.5.2. ALL
Four patients with ALL received treatment according to
the UKALL X protocol (table 2.IV) and the peak CFU-GM/ml
obtained shown in fig 2.11. After induction therapy a 5.3
fold rise in CFU-GM occurred on average on day 24 (range
21 - 29). Intensification, however produced considerably


















FIGURE 2.11 Peak levels of CFU-GM/ml in patients with
acute leukaemia and myeloma treated with various
chemotherapy regimes. The mean values obtained after
each chemotherapy regime is shown as a dotted line and
the mean ± one SEM found in our normal population is
represented by the hatched area.
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CFU-GM/m|
FIGURE 2.12 The reponse of CFU-GM (solid line) and white
blood count (WBC, dotted line) to ADE chemotherapy in a































Table 2.VIII The response of CFU-GM to chemotherapy for
acute leukaemia
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Peak CFU-GM x 103/ml
Chemotherapy course
FIGURE 2.13 The effect on peak CFU-GM/ml of succesive
courses of ADE in 2 patients and of successive courses
of DAT in 3 patients with AML.
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The one patient treated with MACHO increased CFU-GM to
16.8 fold 19 days after receiving high dose Ara-C.
2.4.5.3. Predictors of CFU-GM peaks
In the leukaemic group as a whole, the CFU-GM elevation
started when the mean wcc was 1.5 x 10^/1 and the peak
occurred when the mean wcc was 5.9 x 10^/1. The mean
percentage of monocytes at the time of peak was elevated
at 10.2% (range 1 -29%) (table 2.IX). Although there was
no statistically significant correlation between the peak
CFU-GM and the peak platelet count, it was noteable that
the 2 patients who failed to increase PBSC did not reach
a platelet count above 60 x 10^/1. The rate of recovery
of the wcc did compare with the level of CFU-GM obtained:
those patients who took longer than 5 days to increase
Q ...
the wcc from 1 to 3 x 10/1 had a significantly lower
CFU-GM peak than those who took 5 days or less (p =
0.037, fig 2.14) .
2.4.6. Myeloma
Four patients with myeloma received VAD chemotherapy for
their disease. Three patients had previously
received other chemotherapy regimes. The mean CFU-GM peak




<5 days >5 days
WBC 1-3
FIGURE 2.14 The peak value of CFU-GM is related to the
rate of recovery of the white cell count. The peak values
of CFU-GM/ml reached in those patients with acute
leukaemia whose white blood count rose from 1-3 x 10^/1
in 5 days or less (wbc 1-3 < 5 days) were significantly
greater than the peaks attained by those whose WBC took
more than 5 days to recover from 1 - 3 x 109/1 (WBC > 5
days), (Student's t-test on square root transformed data,
p = 0.037). The data shown represent the mean peak CFU-
GM/ml ± one SEM.
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mean range
WBC at start 1.5 0.2-3.0
x 109/1
WBC at peak 5.9 1.4-25.6
x 109/1
Platelets at peak 212 27-670
x 109/1
Monocytes at peak 10.2 1-29
%
TABLE 2.IX Blood parameters during CFU-GM elevations
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2.5. Conclusion
Standard chemotherapy can induce a rise in PBSC in 85% of
patients with lymphoma and 85% of patients with acute
leukaemia at predictable times. Significantly lower peak
values were found in those lymphoma patients who had




PERIPHERAL BLOOD STEM CELL HARVESTING
Having determined the pattern of stem cell response to
standard chemotherapy regimes, the feasibility of
harvesting these progenitors was assessed.
3.1. Materials
ACD-A (Scottish National Blood Transfusion Service,
Edinburgh)
DMSO (Sigma, Poole, Dorset)
DNAse (Sigma)
Ficoll-metrizoate (Nycomed, Oslo, Norway)
3.2. Patients
After obtaining informed consent and medical assessment,
74 PBSC harvests were obtained from 25 patients with
various haematological malignancies (Table 3.1) at a time
when counts were rising or when previous studies had
indicated PBSC would be raised.
AML was classified according to the FAB criteria (Bennett
et al, 1985), ALL according to MIC criteria (First MIC
Cooperative Study Group, 1986), and NHL according to the
Keil classification (Stansfield et al, 1988). Patients
with lymphoma were clinically staged according to the Ann
Arbor system (Carbone et al, 1971).
Of the patients with NHL, 1 was stage I and 7 stage IV.
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The majority of those with HD also had advanced disease,
5 were stage IV, 2 stage III and one stage I. Patients
with AML consisted of 2 M^, one M2/ one Mj and one .
Two patients had common ALL and one B cell ALL.
DISEASE TARGET MINIMUM
CFU-GM x 10Vkg
START TIMING AND NUMBER
OF PROCEDURES
Acute Leukaemia 30 wcc 1.5x109/l after induction and intensification.
Harvest daily or every other day.
Aim for 5 harvests each time.
Lymphoma during week of 2-3 harvests after each course of
haematopoietic chemotherapy. If no increase in
recovery CFU-GM after 2 courses, stop.
TABLE 3.A CRITERIA FOR PBSCH
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n M/F age(yr) range n PBSCH
NHL 8 4M/4F 43.5 24-56 21
HD 8 7M/1F 32.6 14-57 33
AML 5 3M/2F 31.6 17-46 10
ALL 3 3M 23 17-30 9
Myeloma 1 1M 61 1
TABLE 3.1 Characteristics of patients undergoing PBSCH
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3.3. Methods
3.3.1. Peripheral Blood Stem Cell Harvests
Harvests were performed using the Fenwall CS3000 blood
cell separator set to standard procedure 3 (lymphocyte
collecting procedure) with the interface detector set at
20, centrifuge speed 1400 rev/min and blood flow rate
50ml/min . ACD-A at a ratio of 1:13 with whole blood was
used as anticoagulant. In flow and out flow venous access
lines were established using 14 F gauge cannulae in
peripheral veins or long term indwelling central venous
catheters. A target of 9 litres of blood was processed.
Throughout the procedure the patients were closely
monitored by trained nursing staff. CFU-GM and blood
counts were performed as previously described (2.3.1. and
2.3.5.) before and after each harvest and also on the
product obtained. Collecting efficiencies were evaluated
by calculating the number of circulating cells/ml x
volume blood processed divided by the number of cells
obtained in the harvest x 100.
3.3.2. Secondary Processing and Cryopreservation
In order to reduce red cell contamination and volume of
the stem cell harvest prior to cryopreservation,
secondary processing was performed using an IBM 2991 cell
processor. The method was based on that of Gilmore et al
(1982) for processing bone marrow. The PBSCH was layered
under pressure onto 150ml ficoll-metrizoate and centri-
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fuged at a relative centrifugal force between 905 and
1006 for 25 min. The MNC layer was then collected and
washed twice in 0.9% saline with 20% autologous plasma to
remove the ficoll-metrizoate before being diluted 1:1
with 20% DMSO in autologous plasma, transferred to 2
Gambro bags, frozen using a controlled rate freezer
(Planer PTC 200) and stored at -196°C in the vapour
phase of liquid nitrogen. Five hundred microlitre ali-
quots of the final mixture were withdrawn as pellets and
frozen and stored in a similar manner.
3.3.3. Assessment of Pellet Viability
Cell pellets were thawed rapidly at 37°C (2-3 min)
and immediately mixed with FCS containing 400u/ml DNAse,
lOOu/ml preservative free heparin and 0.015M MgSO^ and
left at room temperature for 10 min. The cells were
washed initially in IMDM, then in IMDM + 5 % FCS and
finally resuspended in IMDM + 2% FCS before being
cultured in the CFU-GM assays as previously described
(2.3.1.). CFU-GM recoveries were assessed at 1, 3, 6, 9,




Seventy four PBSCH were obtained from 25 patients with
haematological malignancies. A mean of 7.72 litres of
blood were processed (range 2.3 - 91) taking between 65
to 200 min (mean 162 min). The contents of the 200ml
product is shown in table 3.II.
The median neutrophil contamination in the PBSCH was 1%,
with 11 harvests containing greater than 5% neutrophils.
The collecting efficiency for CFU-GM was 65.7% (range 0 -
293) and for MNC 55.6% (range 7 - 110). There was no
correlation between the numbers of CFU-GM and MNC
collected (r = 0.13).
3.4.2. Effects of PBSCH on patients
The harvest procedure was tolerated well by the majority
of patients and was performed as an out-patient in 51% of
cases. Poor venous flow was a problem in approximately
15% but only 3 collections were prematurely stopped. The
use of a central venous line for either the venous outlet
or return improved patient tolerance. Two patients had a
vasovagal episode, one confessed to omitting breakfast
after a late-night 1 Both were able to continue with the
harvest on recovery.
Peripheral blood platelets were reduced by a mean of 41%
(range 4-73%) and CFU-GM by 29%, although in 9 patients











2.46 0.1 - 5.61
Table 3.II PBSCH product
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3.4.3. Effects of secondary processing.
After the PBSCH was processed on the IBM 2991, the volume
was reduced to 75ml and the haematocrit to 0.9%. However,
the mean recovery of CFU-GM was 72% (range 0 - 246).
3.4.4. PBSCH in patients with lymphoma
The details of the harvests from patients with lymphoma
are shown in table 3. III. Stem cell harvests yielded a
mean of 0.99 x 10^MNC/kg containing 2.99 x 10^ CFU-GM/kg
per procedure. No correlation was found between the
number of MNC and CFU-GM harvested. In patients who were
harvested after second or subsequent line chemotherapy
significantly lower numbers of CFU-GM were obtained than
from those receiving first line treatment (p = 0.012,








































































































































First Line Second Line +
Chemotherapy
FIGURE 3.1 CFU-GM harvested from patients after first
line or after second or subsequent line chemotherapy.
Significantly lower numbers of CFU-GM were obtained in
those receiving second line or greater therapy than in
those patients harvested during first line treatment (p =
0.012, Student's t-test on square root transformed data).
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3.4.5. PBSCH in patients with acute leukaemia and myeloma
Table 3.IV shows the details of stem cell harvests ob¬
tained from patients with acute leukaemia and one patient
with myeloma. A mean of 1.2 x 10® MNC/kg with 8.6 x 10^





































































TABLE3.IVStemcellharv stsfropatientswithcu el ukaemiadmyeloma.
3.4.6. Pellet Viabilities
CFU-GM recoveries were assessed on 33 PBSCH pellets after
1 month of storage.The mean recovery was 157% of the CFU-
GM in the pellets before freezing. After 3 months 40
pellets showed a recovery of 200%, after 6 months 38
pellets showed 138% recovery, after 9 months 25 pellets
showed 102% recovery, after 1 year 23 pellets showed 70%
recovery and after 18 months 8 pellets showed 50%
recovery (Fig 3.2). There was no significant difference
in the % recovery at one month compared with that at 3, 6
and 9 months but the recoveries at one year and 18 months
were significantly lower (p = 0.018 and p = 0.0039
respectively).
Figure 3.3 illustrates the comparison of growth in the
pellet to that found in the PBSCH Gambro bag at time of
PBSC transplant and shows that in all but patient 7, the
CFU-GM recoveries from the pellets were less than those
found in the PBSCH. The lowest CFU-GM recovery in the
PBSCH at transplant was 85% (patient 3).
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% CFU-GM Recovery
1 3 6 9 12 18
Months
FIGURE 3-2. CFU-GM recoveries from pellets of different
PBSCHs after one to 18 months storage. Results are
expressed as a percentage of the initial harvest growth.
Assessments were performed on the following number of
pellets: one month - 33 pellets, 3 months - 40 pellets, 6
months - 40 pellets, 9 months - 25 pellets, one year -









Pellet PBSCH at transplant
FIGURE 3.3 CFU-GM growth in pellets and the harvest
storage bag from 8 patients at the time of PBSC
reinfusion. The results are expressed as a percentage of
growth obtained at the time of PBSCH and show
discrepancies between pellet CFU-GM and growth of PBSCH
at time of reinfusion.
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3.5. Conclusion
Stem cell harvesting using the Fenwall CS3000 can be
efficiently and safely carried out and collect adequate
numbers of PBSC if harvests are well-timed. Secondary
processing reduced volume and red cell contamination but
resulted in a 28% loss of CFU-GM. Monitoring of





Using gene rearrangement studies, the incidence of tumour
markers in haematological malignancies and in peripheral
blood in patients with NHL at presentation was




Red cell lysis solution
0.14M NH4C1
0.017M Tris pH 7.65
High TE
0.1M Tris pH 7.65
0.04M EDTA
Lysis solution





0.01M Tris pH 7.6
0.001M EDTA pH 8.0
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Tris buffered phenol
0.1% 8-hydroxyquinoline (Sigma, Poole, Dorset) in phenol
equilibrated with 1M Tris until the aqueous phase was
> pH 7.6
RNAse (Sigma, Poole, Dorset, UK) 5mg/ml Boiled for 10
minutes to denature DNase activity





Stock solution 2Ox concentrated
Gel Loading Buffer
0.025% bromophenol blue (Sigma)
0.025% xylene cyanol (Sigma)
2.5% Ficoll 400 (Pharmacia, Uppsala)
Stock solution 6x concentrated











1M Tris pH 5.5
Standard Sodium Citrate (SSC)
1.15M NaCl
0.015M tri-sodium citrate
Stock solution 20x concentrated
Ethidium bromide lOmg/ml (Sigma)
Hybridisation
Denhardt's Solution
0.05% Ficoll 400 (Pharmacia)
0.05% polyvinylpyrrolidone
0.05% Bovine serum albumin (BSA) Fraction V (Sigma)
Stock solution 50x concentrated
Prehybridisation fluid









Sheared salmon sperm DNA 20mg/ml (Sigma)
CTP a^P specific activity 3000Ci/mmol (Du Pont de













Developer solution - GBX developer 20% solution (Sigma)
Fix Solution - GBX Fixer and Replenisher 20% solution
(Sigma)
Stop solution - Indicator Stop Bath 4% solution (Sigma)






All chemicals were analar grade and obtained from BDH
(Poole, Dorset)
4.2. Patients
4.2.1. Gene rearrangements in tumour and presentation
blood
In order to identify tumour markers, gene rearrangement
studies were performed on tumour samples from 18 patients
with AML ( FAB 7, M2 2, M3 3, M4 3, M5 3; 9 male, 8
female; mean age 46.4 years, range 14 - 73), 6 patients
with ALL (5 male, 1 female, mean age 22.5 years, range 16
- 30), 12 patients with NHL (6 high grade, 6 low grade,
mean age 44.1 years, range 15 - 63) and 9 patients with
HD (mean age 33.4 years, range 14 - 51).
Gene rearrangement studies were used to assess the
presence of tumour in the peripheral blood of 36 patients
with NHL at presentation. Seventeen patients had high
grade B cell NHL (mean age 60.2 years, range 41 - 80), 3
patients had high grade T cell NHL (mean age 48 years
range 39 - 57) and 16 patients had low grade B cell NHL.
Six patients had stage I disease, 2 stage II, 8 stage III
and 21 stage IV. Ten patients had bone marrow
involvement.
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AML was classified according to the FAB criteria (Bennett
et al, 1985}, ALL according to MIC criteria (First MIC
Cooperative Study Group, 1986), and NHL according to the
Keil classification (Stansfield et al, 1988) Patients
with lymphoma were clinically staged according to the Ann
Arbor system (Carbone et al, 1971).
Peripheral blood counts were performed as previously
described (2.3.5) and May Grunwald Giemsa stained films
examined by light microscopy for the presence of tumour
cells. Bone marrow involvement was assessed by light
microscopic examination of bone marrow aspirate and
trephine biopsies.
4.2.2. PBSCH
Tumour contamination in 60 PBSCH from 22 patients was
investigated by gene rearrangement studies (Table 4.1).
Of the 7 patients with NHL, 6 were stage IV and one stage
I. Similarly, one patient with HD was stage I, one stage
III and 5 stage IV. Two patients with AML were FAB M-^ and
one M^. Three patients had common ALL and one B ALL.
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mean age
Disease n (range y) M/F lineage




















TABLE 4.1 Characteristics of patients whose PBSCH were




Methods were based on those of Maniatis (Maniatis et al,
1982).
4.3.1. Isolation of DNA
4.3.1.1. Isolation of DNA from blood and bone marrow
Five volumes of red cell lysis buffer at 37°C was added
to one volume of blood or bone marrow and incubated at
37°C for 5 min to lyse the red blood cells. The sample
was spun at 700g for 10 min and the supernatant removed.
The remaining cell pellet was washed twice in 0.9% saline
and resuspended in high TE. The cells were lysed by
adding an equal volume of lysis solution. RNAse A was
added at a final concentration of 50 ug/ml, and incubated
at 37°C for 30 min. Proteinase K was added at a final
concentration of 100 ug/ml and incubated at 40°C for 16
h.
The sample was extracted twice in one volume of Tris
buffered phenol followed by one volume chloroform-isoamyl
alcohol (24:1). The DNA was precipitated by adding 0.5
volume 7.5M ammonium acetate and 2 volumes of absolute
ethanol. The long threads of DNA were spooled on to a
glass rod, washed with ammonium acetate/ethanol (1:2)
then washed with absolute ethanol and allowed to dry
until tacky. The DNA was resuspended in 500pl TE and
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allowed to dissolve at 4°C for at least one week before
use. Dissolved DNA samples were stored at -70°C.
If the DNA concentration was so low that no threads were
seen after the addition of ethanol, the samples were
placed at -40°C overnight, centrifuged at 1600g for 30
min at 4°C . The DNA pellet was resuspended in 1 ml of
70% ethanol, transferred to an mcc tube and centrifuged
at 16000g for 10 min at 4°C. The DNA pellet was dried
under vacuum, resuspended in lOOpl TE and stored at 4°C.
The concentration and purity of the sample were estimated
using UV spectroscopy. Samples were diluted 1:10 with DW
and the absorbance measured at 260 and 280nm. The
concentration of DNA was calculated using the ratio of
1.0 OD2go equivalent to 50pg DNA. The purity of the DNA
was assessed using the ratio OD25Q : 0D2QQ.
4.3.1.2. Isolation of DNA from mononuclear cells
MNC, isolated from blood, marrow or PBSC harvest by
Ficoll-hypaque density gradient centrifugation were
collected in IMDM + 2% FCS. These were spun at 700g for 5
min and the medium discarded. The cells were resuspended
in one volume of high TE to which one volume of lysis
solution was added. The lysate was treated as outlined
previously (4.3.1.1.).
4.3.1.3. Extraction of DNA from tissue samples
Fresh tissue (eg lymph node, spleen) was macerated with a
razor blade as finely as possible, suspended in high TE
and an equal volume of lysis buffer added. The lysate was
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treated as outlined previously (4.3.1.1.).
4.3.2. Digestion of DNA by restriction endonucleases
To 7pg DNA, restriction endonuclease (EcoRI, Hindlll,
BamHI) at a ratio of lOu/pg DNA, an appropriate volume of
lOx concentrated reaction buffer and DW was added to a
final volume of 70 pi. The digest was incubated at the
appropriate temperature for the restriction endonuclease
for 18 h. The reaction was stopped by adding 12 pi of
gel loading buffer.
4.3.3. Separation of DNA fragments by gel electrophoresis
Digested DNA samples were loaded onto a 0.8% agarose gel
in TAE and electrophoresed for approximately 18 h at 50 V
(0.3 - 0.4A) until the bromophenol blue marker dye had
travelled 18cm from the wells. The gel was stained with
0.05% ethidium bromide in TAE for 15 min, destained in DW
for 5 min and photographed under UV light.
4.3.4. Southern blotting
The gel was placed in several volumes of acid hydrolysis
solution to break covalent bonds and shear DNA into
pieces and gently shaken for 30 min with one solution
change. The gel was then transferred to denaturing
solution for 45 min with 2 solution changes, to denature
the double-stranded DNA to single-stranded fragments.
The DNA fragments within the gel were blotted onto a
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nitrocellulose filter by capillary blotting. The gel was
placed on top of a wick of filter paper (2 sheets Whatman
No.6, 3mm paper) supported on a glass plate, with the
ends of the wick submerged in 20x SSC solution. A
nitrocellulose filter, cut to the same size as the gel
and soaked in 2x SSC, was placed carefully on top of the
gel. Above this was placed 3 sheets of filter paper
(Whatman No.6) cut just larger than the size of the gel,
a 15 cm pile of paper towels, a glass plate and a brick.
Capillary blotting occurred over 18-24 h, changing the
saturated paper towels when necessary.
The filter was retrieved, marked and washed in 2 x SSC
and baked for 2 h at 80°C. The filters were stored at
room temperature.
4.3.5. Probes
The probes used were a 2.5 kb EcoRl - Bglll fragment
containing the IgHJ region (Flannagan et al, 1982), 0.8
kb SacI - Xhol fragment containing the TCR C/31 gene
(Gledhill et al, 1990) and a 1.8 kb SacI fragment of the
region 3' to the TCRJ61 (J6S16 probe) (Boehm et al,
1988). DNA probes were derived from the plasmids by
cleavage with an appropriate restriction endonuclease,
electrophoresed in low melting temperature agarose, and
the appropriate DNA fragments to be used as hybridisation
probes cut out of the gel. The probes were extracted once
in phenol/chloroform/isoamyl alcohol (25:24:1) and
precipitated for 60 min at -20°C after addition of 0.1
volumes of 3M sodium acetate (pH 5.2) and 2 volumes of
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absolute ethanol.
The probes IgHJ, TCR/3 and TCR6 were radioac t ive ly
labelled by the random primer oligolabelling method based
on that of Feinberg and Vogelstein (1983 & 1984) to a
specific activity of not less than 8 x 108cpm/jjg DNA. To
a volume containing 25ng of linearised probe DNA was
added 3 ul 0•5M nucleotide (dATP, dGTP and dTTP) solu¬
tion, 2ul hexanucleotide and buffer solution, 2U Klenow
enzyme and 5ul 8^P-labelled d-CTP (50 uCi) This was
incubated at room temperature overnight. To ascertain
incorporation of radioactivity, a spot of the reaction
mixture was placed on GF/B filter and this was trans¬
ferred to 10ml 5% TCA in a scintillation vial and the dpm
measured on a /3 counter. The filter was retrieved, incor¬
porated radioactivity precipitated with 5% TCA and the
dpm counted. The incorporation was expressed as a per¬
centage of the initial count. The sample was passed down
a sephadex column to remove unincorporated nucleotides,
and the specific activity of a 2 ul sample in 5 ml of
scintillant was measured using a scintillation counter.
The probes were used immediately.
4.3.6. Prehybridisation, hybridisation and washing
4.3.6.1. Prehybridisation
Twenty ml of prehybridisation solution and 2.5 mg
sonicated salmon sperm DNA (heated to 100°C for 10 min
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and snap-cooled on ice to denature the DNA) was added to
a polythene bag (Hybaid system) containing the filter to
be probed and incubated at 65°C for at least 5 h.
4.3.6.2. Hybridisation
The prehybridisation solution was drained from the bag
and to this was added the radiolabelled probes, plus a
further 2.5 mg sonicated denatured salmon sperm DNA. This
mixture was returned to the bag, inverted several times
to ensure uniform bathing of the filter and the air
removed. The filter was incubated at 65°C for 16 h.
4.3.6.3. Washing
Using the Hybaid apparatus the filter was washed with
wash solution 1 for 5 min at room temperature and the
radioactivity remaining in the bag monitored with a hand
held Geiger counter. Depending upon the probe used and
the monitored counts, wash solution 2 and then wash
solution 3 were used for 5 min at 65°C until the counter
registered <2 cps.
4.3.7. Autoradiography
The filter was wrapped in cling film and mounted in an X-
ray cassette next to an X-ray photographic film and
left at -70°C. The film was developed in developer
solution for 5 min, transferred to a stop bath for 30
seconds and fixed in fixative for at least 2 min
before being washed in tap water for 30 min and dried.
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4.3.8. Re-probing of a filter
The probe was removed by immersing the filter in probe
stripping solution for 10 min, washing in 2x SSC and then
exposing the filter to an X-ray film to check
completeness of stripping.
4.4. RESULTS
4.4.1. Gene rearrangements in tumour samples
4.4.1.1. Acute leukaemias
Of the 18 patients with AML, 3 (17%) had rearranged bands
when studied with TCR6. An example of an autoradiograph
probed with TCR6 is shown in fig 4.1. These patients had
AML of different FAB types (1 M-^, IM2 and lM^) and only
one was Tdt positive. Three other patients with Tdt
positive AML (2M-^, lM^a) demonstrated no TCR6
rearrangements.
The 6 patients with ALL had disease of the B cell lineage
and all demonstrated rearranged bands when probed with
IgHJ. An autoradiograph of DNA from a patient with ALL
probed with IgHJ is shown in fig 4.2. Four of the
patients were also studied with TCR6 and all showed
rearrangements (Table 4.1).
4.4.1.2. Lymphomas
All 8 patients with B cell NHL (2 high grade, 6 low
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grade) had IgHJ rearrangements in their tumour. Three of
the 4 patients with high grade T cell NHL had TCR/3
rearrangements but one with large cell anaplastic NHL
showed only germline configuration when probed with IgHJ,
TCR/3 and TCR6. No tumour marker bands were found in any
of the 9 patients with HD probed with TCR6 or 5 probed




AML 0/3 n/d 3/18 (17%)
ALL 6/6 n/d 4/4
B NHL high 2/2 0/1 n/d
T NHL high 0/4 3/4 (75%) 0/3
B NHL low 6/6 n/d n/d
HD 0/5 n/d 0/9
14/26 3/5 7/34








Hind III Bam HI
FIGURE 4.1 Autoradiograph ofDNA from 4 patients with AML probed with
TCR8. Tonsil DNA (T) was used to indicate germline configuration. A tumour
marker bandwas demonstrated in patient 1. This measured 7.4kb after the DNA
was digested with Hind III and 14.8kb after digestion with BamHI. Patients 2,3
and 4 produced only germline bands.
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T 5% BM T 5% BM
germline ->
11.7 kb ->





FIGURE 4.2 Autoradiograph of DNA from a patient with ALL probed
with IgHJ. Tonsil DNA (T) was used to indicate germline configuration.
A tumour marker band was demonstrated in the patient (BM). This
measured 11.7kb after the DNA was digested with EcoRI and 15.5kb after
digestion with BamHI. The sensitivity of the technique was determined by
dilution of a cell line with an IgHJ rearrangement in normal DNA. A cell
line marker band was demonstrated at a concentration of 5% confirming
the level of sensitivity.
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4.4.2. Gene rearrangements in presentation blood in
patients with NHL
As 8 of 8 patients with B cell and 3 of 4 patients with
T cell NHL had tumour marker bands presentation blood
samples were assessed for tumour involvement using IgHJ
and TCR/3 gene probes. Of the 36 patients studied, 7
(19.4%) had rearrangements detectable in their peripheral
blood. This included 3 of 20 (15%) patients with high
grade disease (3/17 B cell, 0/3 T cell) and 4 of 16 (25%)
with low grade disease (all B cell). Conventional
microscopic examination of blood films detected tumour
cells in only 2 of these 7 patients.
Peripheral blood gene rearrangements were more often
found in stage III/IV disease (21%) than in stage I/II
(12.5%) and occurred in 40% of those with bone marrow
involvement. Despite the bone marrow appearing
histologically clear of disease in 26 patients, 3 (1/20
high grades and 2/16 low grades) had evidence of gene
rearrangements in the blood (11.5%).
Bone marrow gene rearrangements studies were performed in
24 patients (12 high grade, 12 low grade) and marrow
involvement found in 7 (29%). In 4 (57%) of these
patients examination of bone marrow trephine and marrow
aspirate had failed to demonstrate malignant cells. In
one patient, marrow involvement found on microscopic
examination failed to be detected by DNA examination.
96
4.4.3. Gene rearrangements in PBSCH
The results of Southern blotting analysis of PBSCH in
patients with AML and HD are shown in table 4.III. As
tumour markers were not found with any probe, the PBSCH
were unable to be assessed for tumour contamination by
gene rearrangement analysis.
All patients with ALL, 3 of 4 patients with high grade
NHL and all patients with low grade NHL had tumour
markers demonstrable by gene rearrangement analysis. An
identical rearrangement to the tumour was found in the
presentation bone marrow of 3 patients and in the
peripheral blood of 1 patient with NHL. No rearrangement
was found in any of the PBSC harvests using this tech¬
nique (Table 4.IV). The results of gene rearrangement
studies from 2 patients with NHL are shown in figs 4.3
and 4.4.
97
Disease Patient Probe Tumour PBSC(n)
AML FC TCR6 G G( 3)
KD TCR6 G G (2)
SW TCR6 G G (2 )
HD DB TCR6 G G (2 )
IgHJ G G
GM TCR6 G G( 2 )
IgHJ G
EN TCR6 G G (1)
IgHJ G G
DO TCR6 G G (3)
IgHJ G G
BP TCR5 G G (2)
IgHJ G G
TCR/3 G G
AS TCR6 G G( 5)
IgHJ G G
LT TCR5 G G (3)
IgHJ G G
TABLE 4.Ill Gene rearrangement studies on PBSCH from
patients with AML and HD.
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Disease Patient Probe Tumour PBSC
ALL GG IgHJ R G (1)
TCR6 R G
WL IgHJ R G (3)
TCR6 R G
BM IgHJ R G (1)
TCR6 R G
DP IgHJ R G
TCR6 R G
NHL RB IgHJ R G (2)
(high grade) TCR/3 G G
TCR6 G G
MA IgHJ G G( 2 )
TCR/3 G G
TCR6 G G
TH TCR/3 R G (4)
TCR6 G G
MP IgHJ G G( 5)
TCR/3 R G
TCR6 G G
NHL AM IgHJ R G (3)
(low grade) SP IgHJ R G (6)
LW IgHJ R G (2 )
Myeloma JB IgHJ R G (1)
TABLE 4.IV Gene rearrangement studies on
patients with ALL , NHL and
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4.5. Conclusions
Gene rearrangement studies identified tumour markers in
all patients with ALL, 17% of AMLs, 92% of NHLs and in no
patients with HD. Of the patients with NHL, 19.4%
demonstrated gene rearrangements in the blood at
presentation which was more often found in patients with
advanced disease and bone marrow involvement. Light
microscopy failed to demonstrate blood contamination in
70% of these cases and in 58% of patients with gene
rearrangements detected in marrow samples. Because of the
lack of tumour markers for AML and HD gene rearrangement
studies were useful for assessing tumour contamination in
only 60% of PBSCH, but in these no evidence of disease
was found.
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FIGURE 4.3 Autoradiograph of DNA digested with EcoRl from
a patient with high grade B cell NHL probed with IgHJ.
Tonsil DNA (C) was used to indicate the 13.1kb germline
band. A tumour marker band measuring 9.0kb was
demonstrated in tumour (T) and marrow (M) but not in
blood (B) or 2 PBSCH (SI and S2).
101





FIGURE 4.4 Autoradiograph of DNA digested with EcoRl from
a patient with high grade T cell NHL probed with TCR/3.
Tonsil DNA (C) was used to indicate the 8.9kb, 7.8kb and
4.2kb germline bands. A tumour marker band measuring
3.7kb was demonstrated in tumour (T) and marrow (M) but




In order to increase the availability of autologous
transplantation for patients with haematological
malignancies, blood was investigated as an alternative
source of stem cells. The response of PBSC was
characterised after standard chemotherapy for
haematological malignancies and the feasibility of
harvesting these progenitors established. The harvest
obtained was assessed for tumour contamination. These
studies will now be discussed.
5.1. The CFU—GM assay
The ability of transplanted marrow to reconstitute and
sustain haematopoiesis can be predicted not only by the
measurement of CFU-GM (Spitzer et al, 1980) but also by
the numbers of MNC infused (Gorin, 1986). As marrow MNC
are considerably easier to measure than CFU-GM and give
reproducible results from centre to centre they are used
more frequently as a guide to dose.
The situation is quite different in the peripheral blood.
Because of the flux of PBSC numbers in response to
factors such as chemotherapy, the numbers of MNC do not
correlate with CFU-GM or reconstitutive ability, and thus
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are of little or no value. Progenitor cell culture assays
are therefore of paramount importance as a guide to stem
cells in the peripheral blood.
5.1.1. Standardisation of the CFU-GM assay system
The basic CFU-GM assay has several inherent problems that
lead to variable reproducibility between centres and even
within institutions. The assay is not standardised; the
support material may be methylcellulose, as used in this
study, or agar; FCS has variable growth promoting
activity and this must be checked prior to batch changes;
conditioned medium can be obtained from peripheral blood
lymphocytes, placenta or from cell lines; colony counting
shows inter and intra-observer variation.
In an attempt to minimise this variability, the following
steps were taken:
1. The accurate identification of colonies was initially
established by comparing photographs of the colony in
situ on the plate with photographs taken after the colony
had been removed and stained. Thus identification of
colonies containing only one lineage of cell could be
distinguished from those of mixed lineage and this
operator skill could be checked at intervals.
2. In peripheral blood the number of accessory cells
present has been reported to produce an inhibitory effect
on CFU-GM at high plating concentrations (To et al, 1983)
and result in a non-linear plating concentration effect.
In the assay system used in this study, there was no
obvious inhibition of growth, a linear relationship
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between MNC plating numbers from 0.5 - 8 x 10 and
colonies per plate was observed for both normals and stem
cell harvests. The optimal plating concentration was
chosen as 2 x 10®MNC/plate without monocyte depletion.
3. To standardise the conditioned medium, peripheral
blood lymphocytes derived from one healthy donor after a
period of exercise were used.
4. In order to monitor variability in the assay with
time, to establish a normal range for our laboratory and
to compare results with those from other centres,
circulating CFU-GM from normal volunteers was assessed
throughout the 3 year study period. No significant
difference was found between normal results from
different periods (p = 0.38) confirming the assay was
consistent.
The mean value of 166 ± 19 CFU-GM/ml blood in the normal
group is comparable to other normal values reported. A
similar methylcellulose culture system with PHA LCM but a
plating concentration of 1 x 10® MNC per plate was used
by a group in Italy who found the mean CFU-GM growth in
18 normals to be 251 ± 53 (1 SEM) (Carlo-Stella et al,
1987). A similar system was employed in Canada, plating
at 3 x 10®MNC where 12 normal samples had a mean value of
60 CFU-GM per ml, range 7 - 168 (Cantin et al, 1989) .
Lasky et al, 1982 reported an even lower mean at 40 CFU-
GM/ml. These figures demonstrate the amount of inter-
laboratory variation despite similar culture systems.
Other workers using methylcellulose and feeder layers
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have found ranges of 20 - 150 CFU-GM/ml (partanen et al,
1982), 40 - 120 CFU-GM/ml (Chervenick, 1973) and 6 - 200
CFU-GM/ml (Hibben et al, 1984), whilst those working with
agar systems have reported normal CFU-GM values of 149/ml
(range 31 - 362) (Korbling et al, 1980) and 110/ml (95%
confidence intervals 23 - 490) (To et al, 1989).
In an attempt to circumvent the interlaboratory variation
in normal values the peak values obtained after
chemotherapy are compared to those from normals and
expressed as a proportional increase above the mean.
5.1.2. Future improvements in PBSC identification
Despite meticulous aseptic technique, sterilisation
procedures and multiple antibiotics, bacterial and fungal
infection occurred periodically, especially when any
repair or reconstruction work was being done in the
vicinity of the department. The 2 week incubation period
was a major drawback to the system as results were not
available quickly to aid clinical decision making.
However, despite its disadvantages, the CFU-GM assay at
the time represented the best experimental assessment of
haematopoietic progenitor cells as it is the most studied
and most widely accepted predictor of haematopoietic
reconstitutive capacity.
Many of the disadavantages of the progenitor cell assay
system may be overcome by the use of immunophenotyping.
Recently it was demonstrated that CD 34+ cells in the
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circulation detected by dual colour direct
immunofluorescence flow cytometry after PBSC mobilisation
correlated well with CFU-GM (Serke et al, 1991; Siena et
al, 1991). Subpopulations of these CD34 + cells were found
to express CD33 and these correlated with early
haematopoietic recovery of marrow function, predicting
this more accurately than total MNC or CFU-GM infused
(Siena et al, 1991). If confirmed, this method will
provide rapid, accurate and reproducible guidelines for
estimation of peripheral blood stem cells.
5.2. PBSC after chemotherapy
The continued debate over the minimum numbers of
circulating CFU-GM required to sustain engraftment in
various disorders highlights its lack of reliability as a
predictor of engraftment. Until a more reliable predictor
is found, the aim of PBSC collection must be to collect
as many progenitor cells as possible. This may be
maximised if PBSC harvests are performed when the stem
cell pool is expanded as, for example, on recovery from
chemotherapy. The most studied group of patients are
those with AML where chemotherapy has produced an 11 - 25
fold increase in CFU-GM in early remission (To et al,
1984; Giessler et al, 1986) which have been successfully
transplanted. In patients with solid tumours a 14 fold
rise in CFU-GM was demonstrated after chemotherapy for
small cell carcinoma of lung (Stiff et al, 1987), a 20
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fold increase after treatment for ovarian cancer (Richman
et al, 1976) and a 10 fold increase after IMVP16 for
lymphoma in 2 patients (Bell et al, 1987b). Recently the
introduction of high dose schedules such as
cyclophosphamide 4g/mz to specifically induce a rise in
PBSC has been reported. A mean 14 fold rise predictably
occurred in 69% of patients, but with significant
morbidity and even mortality (To et al, 1990). The
precise response to standard chemotherapy regimes,
however, such as CHOP, ALL, ChlVPP, MOPP, for patients
with lymphomas has not been reported and these may
represent a less toxic way of inducing a stem cell
increment.
5.2.1. PBSC after treatment for acute leukaemias.
In AML, this study demonstrated a 38 fold increase in
CFU-GM over normal values after DAT chemotherapy
occurring on average at day 28.6 after the start of
treatment, and a 12.5 fold increase after ADE at day 26.
No rise in circulating progenitors was found in 2
patients neither of whom entered remission after the
first course of treatment. An extremely large rise in
PBSC was found in one patient with AML after DAT 1
(34,243/ml), however, he was not in remission and also
had a high blood CFU-GM prior to treatment. It seems
likely that these PBSC may be contaminated with the
malignant clone.
Patients with ALL also demonstrated increased CFU-GM to
5.3 fold after induction therapy at day 24 and a larger
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increase after intensification to 35 fold at day 26. All
demonstrated an increase in CFU-GM, including one patient
who did not enter remission although his results are the
lowest for both induction and intensification.
These reults are in general agreement with other reports
where mean increases ranging from 5.6 to 25 fold have
been reported after DAT type therapy for AML (To et al,
1984; Cantin et al, 1989). PBSC increases reported here
with DAT are considerably higher than those reported by
Reid et al despite a similar chemotherapy regime.
However, Reid quoted no normal values for his laboratory
limiting direct comparisons with my results, additionally
the numbers of patients studied were small. Only 3 of
Reid's patients were receiving first induction treatment
and it was emphasised that circulating CFU-GM fell
markedly with repeated courses of treatment (Reid et al,
1989). The differences in the levels of CFU-GM after
chemotherapy in the present study, as shown by the large
ranges (Table 2.VIII), stresses the variability of PBSC
peaks and the difficulty in predicting when to collect
PBSC.
In contrast, the levels of progenitors found after
intensification therapy for ALL were very similar to
those demonstrated by Reid and occurred at consistent
times.
A factor associated in the present study with a high CFU-
GM peak after chemotherapy was a rapid recovery from
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myelosuppression, as indicated by the the time taken to
increase the total white cell count from 1 to 3 x 10^/1.
Others have used the rapid recovery of monocytes or
platelets to monitor this (To et al, 1990; Cantin et al,
1989; Reid et al, 1989). Two successive courses of
chemotherapy did not significantly reduce the mean peak
of the group as a whole, however the numbers were small
and variations in response were seen when patients were
considered individually (Fig 2.4). There was no evidence,
however, of the major reduction in peak values after
these 2 courses, as found by Reid et al, our results
being more in keeping with those of Cantin et al, 1989
who found no relationship between the levels of CFU-GM
and the number of DAT cycles administered.
Thus, for patients with leukaemia it was considered that
to maximise PBSC harvested, leukapheresis should start in
first remission, at times determined by the specific
regime. This should occur usually after the total WCC
increased to greater than 1 x 10^/1 and as counts were
rapidly rising over a period of 5 days. The leukapheresis
should be repeated after at least the second course of
chemotherapy.
5.2.2. PBSC after treatment for lymphoma
In patients with lymphoma, sampling was performed less
freguently than in patients with leukaemia. The major
reason was patients with lymphoma were predominantly
treated as out-patients whereas those with acute
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leukaemia stayed in hospital throughout the period of
myelosupression which was more severe and prolonged.
Because of a lower sampling frequency, it is possible
that CFU-GM peaks were wholly or partially missed, and
accurate predictors of recovery such as those studied in
patients with acute leukaemia, could not be fully
assessed.
Despite these limitations, standard chemotherapy regimes
for lymphoma induced a documented rise in circulating
CFU-GM in 87% (40/46) of patients. In those patients with
high grade NHL, the increase found after ALL induction
therapy (17.5 fold) was higher than after induction
therapy in patients with ALL (5.3). The increase occurred
a little earlier and may reflect the lack of marrow
infiltration by malignant cells in the patients with NHL.
Patients treated with CHOP based regimes demonstrated a
6.9 fold increase in CFU-GM, with only one patient having
no documented rise, PEEC gave very large increases to 48
fold. These levels of PBSC are comparable to those found
in other patients with lymphoma (Bell et al,1987b), solid
tumours (Richman et al, 1976; Stiff et al, 1987) and
acute leukaemia (To et al, 1987a) and therefore should
yield reasonable numbers of PBSC for transplantation. The
timing of progenitor peaks for out-patients was generally
towards the end of the third week of the chemotherapy
cycle as counts were recovering and monocytes were
elevated (mean 12.5%).
Less intensive regimes for low grade disease produced
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only minor increases in CFU-GM and therefore patients
were not considered for PBSC harvesting.
Standard chemotherapy for HD resulted in a less frequent
mobilisation of PBSC. This may have reflected the patient
population, as 6 had undergone previous chemotherapy
regimes and 3 had bone marrow involvement both of which
produced significantly lower CFU-GM peaks in the lymphoma
group as a whole (figs 2.9 & 2.10). The more prolonged
type of chemotherapy regime or the inclusion of
chlorambucil which damages early stem cells, eg ChlVPP,
OPEC, may also reduce stem cell mobilisation. Large
increases were seen after HOPE which contained 40mg/m^ of
adriamycin and produced considerable myelosuppression
with subsequent CFU-GM rebound.
Thus, standard chemotherapy for lymphoma can induce a
rise in PBSC in the majority of patients with lymphoma.
Higher peaks are found in those receiving first line
chemotherapy and in those without marrow involvement. As
previous chemotherapy diminishes the response of CFU-GM,
in those patients with a high risk of relapse, harvesting
of progenitors should be performed during first line
chemotherapy after the first course of treatment as white
cell counts are recovering and should be repeated after
each cycle.
5.2.3. Myeloma
A group of patients with myeloma were studied, but
results were inconclusive. Only a small number of
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patients were studied, 75% of whom had received previous
treatment and all of whom had diseased marrow. PBSC
increases were poor. In such patients, high dose
chemotherapy such as cyclophosphamide 7g/m , is required
to mobilise sufficient PBSC for autografting (Marit et
al, 1990; Bell et al, 1990).
5-3. Other approaches to PBSC mobilisation.
Apart from standard chemotherapy for malignancies, PBSC
have been mobilised using high doses of chemotherapy, in
particular cyclophosphamide (Marit et al, 1990; To et
al, 1990). This approach, which has significant side
effects, increased stem cells in 69% of cases but was
less successful in those with over 20% marrow
infiltration and previous myelotoxic chemotherapy which
may constitute a significant number of patients who could
potentially benefit from PBSCT.
The recent cloning of various haematopoietic growth
factors has led to their production in sufficient
quantity and purity for clinical study. G-CSF stimulates
the production and function of granulocytes and shortens
the period of neutropenia after chemotherapy and bone
marrow transplantation (Gabrilove et al, 1988; Teshima et
al, 1989). Dexter's group demonstrated the presence of
substantial numbers of primitive stem cells in the
peripheral blood of mice after G-CSF treatment, which
were capable of reconstituting the haematopoietic system
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in the long term and of contributing to the lymphoid
populations of the thymus when transplanted into
irradiated mice (Molineux et al, 1990). In man, evidence
exists that the less lineage specific growth factor GM-
CSF has also shortened the period of neutropenia after
BMT (Brandt et al, 1988; Nemunaitis et al, 1988) but
with more side effects than G-CSF.
GM-CSF was used in combination with 7g/m
cyclophosphamide to mobilise CFU-GM. Together these 2
modes of treatment increased CFU-GM up to 1000 fold
(Gianni et al, 1989). These progenitors were harvested
and reinfused together with bone marrow after which, in
some cases, further treatment with GM-CSF was given.
Rapid haematopoietic reconstitution was observed, however
the contribution made by the GM-CSF mobilised CFU-GM is
unclear and their ability to sustain long term
haematopoiesis was not established. Haas used GM-CSF
alone to mobilise CFU-GM in patients with non-myeloid
malignancies and found a mean increase of 8.5 fold after
10 days. These were harvested and reinfused to 6 patients
after myeloablative treatment and restored adeguate
haematopoiesis in 5 with a follow up of a median of 103
days (Haas et al, 1990).
Thus, the use of growth factors to mobilise stem cells
appears promising but their ability to maintain long-term
haematopoiesis in man has yet to be established. An
interesting approach will be the use of G-CSF after
standard chemotherpy to both shorten the periods of
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neutropenia and possibly increase circulating PBSC in
particular in those heavily pretreated individuals or
those with marrow infiltration.
5.4 PBSC Harvests
Having established the occurrence and timing of CFU-GM
increases after standard chemotherapy regimes for
lymphoma and leukaemias, PBSC were harvested using a
Fenwall CS3000 continuous flow cell separator. This
machine offered operator independent consistency, being
fully automated under computer control. As stem cells
were found in the lymphocyte fraction of blood programme
3 (lymphocyte collection) was selected.
5.4.1. Clinical problems associated with PBSCH
During the initial assessment period 7 litres of blood
were processed, but this was increased to a target volume
of 9 litres. Five litres were processed in a boy of 14
who weighed only 33 kg and in one patient the procedure
was terminated after 2.3 litres due to severe venous
spasm. Not surprisingly, obtaining adeguate venous access
was difficult in some of those patients who had received
irritant chemotherapy. The majority of such patients had
long term indwelling central venous catheters inserted
for drug administration and venous sampling. Adequate
venous out-flow rates could be achieved through a Raaf
double lumen catherter (Quinton, Kimal scientific
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products ltd, Uxbridge) internal dimensions 1.2 x 3mm. The
return line could then be attached to a smaller 16G
cannula. If an adequate out flow line could be
established peripherally then the return line could be
connected to a central line of various diameters (Quinton
triple lumen catheters internal dimension 1.0mm, double
lumen catheters internal dimension 1.5mm). The patients
found this a more comfortable arrangement as it allowed
one arm free for drinking, reading, etc.
Two patients who had vasovagal attacks both recovered
fully and were able to continue with the procedure and
subsequent harvests. One gentleman became very anxious
anticipating the procedure and the other omitted
breakfast after a busy night of socialising. No other
major complications (in particular severe headache as
reported in patients with intracranial pathology on
intermittent flow leucapheresis (Smith et al, 1990)) were
encountered. Apart from the comment that the harvests
could be rather tedious, being confined to a bed or chair
for 3 hours, and the minor discomfort of cannulae
insertion, the patients tolerated the procedure well;
about half being performed as out-patients. No-one
complained of paraesthesia due to hypocalcaemia from
citrate toxicity as has been reported (To et al, 1989)
although we have seen this recently in further studies
with the Cobe Spectra.
Despite a 41% reduction in the circulating platelet
numbers after the harvest, there was no evidence of
116
clinical bleeding. However, if possible, harvests were
deferred until platelets were greater than 35 x 10^/1 or
a platelet transfusion was given at the end of the
procedure.
5.4.2. Product specification
The CFU-GM collecting efficiency of 65.7% in the CS3000
is comparable to that in patients with AML (58 - 73%) (To
et al, 1989), in normal volunteers (64%) (Lasky et al,
1982) and in patients with leukaemia and lymphoma (76%)
(Vannier et al, 1989) all harvested on the CS3000.
However, the 200ml product obtained from the CS3000
contained significant red cell contamination with a
haematocrit of 17% and a relatively high number of
platelets (mean 2.5 x 10*1) which resulted in a 41%
reduction in circulating platelets . Similar reductions
in platelets have been reported using the CS3000 (Lasky
et al, 1982), or the Haemonetics V50 (Schouten et al,
1990).
5.4.3. Advances in PBSC harvesting
In order to obtain adequate numbers of PBSC for
engraftment, several apheresis procedures must be
performed and the products cryopreserved. At the time of
transplant there is generally a larger volume of product,
including DMSO and red cells, to be returned to the
patient than during BMT. Toxicity such as tachypnoea and
elevations in serum bilirubin and creatinine can result
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from large volumes of DMSO and contaminating red cells
(Kessinger et al, 1990). The ideal stem cell harvest
product should, therefore, be in a small volume with
minimal red blood cell, polymorph and platelet
contamination.
In order to reduce the numbers of platelets removed
during the harvest, modified protocols have been
investigated. Williams et al used a modified programme 1
(platelet collection) on the CS3000 with the interface
detector set at 100, the centrifuge speed dependent on
the patients haematocrit and giving a final soft spin at
the end of the procedure to return platelet rich plasma
to the patient. This collected between 2 - 4 x 10^1
platelets with a 5% loss of MNC (Williams et al, 1990).
Other groups have reported a lower CFU-GM collecting
efficiency with programme 1 (Iacone et al, 1990). Similar
modifications were investigated on the Haemonetics V50
where adding a lymphocyte surge to the standard programme
reduced platelet loss by 40% and also reduced red cell
contamination. Similar numbers of CFU-GM were collected
by both methods indicating there may be some benefit in
this modification without compromising the final product.
Modifications to harvesting technology are being
developed for the CS3000 with the introduction of a small
collection chamber and modified computer programme to
reduce the volume of the product and red cell and
platelet contamination. The COBE Spectra cell separator
is currently being evaluated in this laboratory for its
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ability to produce a similar product.
5.4.4. Secondary processing
In view of the product obtained from the CS3000 and the
risks of red cell and DMSO reinfusion, the harvest was
purified by secondary processing over ficoll using an IBM
2991 cell processor. The goals of volume reduction and
red cell depletion were achieved, but a 28% loss of CFU-
GM occurred and the procedure itself was very time
consuming and expensive. The use of a cell processor
however, had an advantage over manual techniques for
cell separation as it used a closed system and thus
reduced the risk of microorganism contamination. Law et
al reported no bacterial or fungal contamination using a
Haemonetics V50 to separate MNC from 30 donor units (Law
et al, 1988).
In a letter, Duoay et al recommended ficoll purification
of PBSC which produced superior CFU-GM recoveries (79%)
after cryopreservation, compared with only a 19% CFU-GM
recovery in those unseparated PBSC. He suggested that
unseparated cells were more easily damaged during cryo¬
preservation (Duoay et al, 1989). Unfortunately the full
methods were not detailed in his letter, but perhaps if
the harvests were contaminated with granulocytes the
cells would be more likely to clump after cryopreserva¬
tion. In contrast, Kessinger et al found that PBSC
harvests separated over ficoll resulted in delayed en-
graftment suggesting damage or loss during processing
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but she did not comment upon CFU-GM recoveries (Kessinger
et al, 1990). Thus the role of ficoll separation remains
unclear but the present study found loss of CFU-GM during
the procedure.
5.4.5. Pellet Viabilities
In this study, CFU-GM culture studies of pellets to
monitor viability of stored PBSC harvests may not be an
accurate reflection of growth in the bulk PBSCH. Vital
dye exclusion (eg trypan blue) is inadequate for
assessment of progenitor survival. This method depends
upon the ability of viable cells to exclude dyes and will
measure damage to many cell populations. There is
disparity between dye exclusion and CFU-C survival after
freezing (Gray and Robinson, 1973) suggesting that other
nucleated cells are lost preferentially. Measurement of
CFU-GM recovery on pellets compared to the original
product after processing, showed no loss of viability
until 12 months when the growth was reduced by 30%.
However, the growth in pellets did not appear to
correlate with the actual growth found in the stored bags
of PBSC at the time of reinfusion to patients. This
observation has been noted by other workers (Foures et
al, 1990). The most likely explanation lies in the
storage and handling of pellets which are otherwise
prepared and frozen in exactly the same way as the PBSC
harvest. Once frozen in liquid nitrogen the pellets are
stored in separate racks from the harvests which are
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removed at regular intervals from the liquid nitrogen
tanks in order to find other pellets from marrow and PBSC
harvests for assessment. As the pellets contain only 0.5
ml the cells are probably subjected to temperature
variations resulting in cell death.
5.4.6. Progenitors Harvested
Wide variations in CFU-GM dose have been reported to
produce haematopoietic reconstitution, but it would
appear that in non-leukaemic disorders a lower dose may
be sufficient. For patients with AML doses of 30 - 50 x
10^/kg are capable of engraftment while in other
disorders CFU-GM above 5 x 10^/kg result in rapid
reconstitution (Korbling and Martin, 1988).
Overall, the CFU-GM yields were limited by similar
factors that affected the CFU-GM peaks after standard
chemotherapy regimes.
5.4.6.1. PBSCH in patients with lymphoma
In the group of lymphoma patients as a whole, a mean of
0.99 x 10® MNC/kg per procedure containing a mean of
2.93 x 10^CFU-GM/kg were obtained (Table 3.III). In
patients with NHL, the highest numbers of CFU-GM were
harvested from those treated with ALL chemotherapy which
is in keeping with the higher circulating CFU-GM found
after this regime in the initial study. Two patients (SL
and SP) had only 1 procedure carried out because of
venous access difficulties. In the other patients,
despite relatively few proceedures (2 - 5) more than 5 x
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10^ CFU-GM/kg in total were obtained. Current policy is
to perform if possible, at least 2 PBSCH after each pulse
of chemotherapy.
In patients with HD lower yields were obtained. One (EN)
had the procedure terminated after only 2.3 litres
because of venospasm, resulting in a poor harvest. Two
patients (BP and GL) had harvests resulting in good CFU-
GM yield after only 2 or 3 passes. The other patients
(except AS) were all receiving 2nd line or greater
chemotherapy which reduced the amount of circulating CFU-
GM and numbers harvested. Patient AS had bone marrow
involvement which resulted in lower PBSC and in addition
was receiving ABVD which only produced CFU-GM increments
in 6/9 of our patients.
5.4.6.2. PBSCH in acute leukaemia
More CFU-GM were harvested from the group of patients
(Table 3.IV) with leukaemia than those with lymphoma
reflecting the higher CFU-GM peaks found after this form
of chemotherapy. Relatively few CFU-GM were collected
from GG because of mis-timing of the harvest and from KD
who was receiving the second pulse of treatment for first
relapse and thus was heavily pre-treated. FC, SW and JH
were harvested after MACE and MidAc which are the third
and fourth pulses of chemotherapy for AML in the MRC AMLX
protocol. The response of PBSC after these chemotherapy
regimes had not been included in this study, but others
have shown that in AML, after 2 courses of treatment
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there can be a fall in CFU-GM (Reid et al, 1989). In 3
patients who had well timed harvests after first or
second courses of chemotherapy (DC, DP and WL) good CFU-
GM yields were obtained.
Thus, PBSC harvesting after standard chemotherapy can be
successful if performed with correct timing and after
early courses of treatment in patients with acute
leukaemia, NHL and some patients with HD, depending on
the regime used. For those patients who have had previous
chemotherapy or those with marrow involvement other means
of stem cell mobilisation may have to be considered.
5.5 Gene rearrangements in haematological malignancies
Gene rearrangement studies may be a useful tool as a
tumour marker in haematological malignancies, however
there are several limitations to the technique. One of
the most significant disadvantages is low sensitivity.
Using dilution experiments with cell lines and normal DNA
tumour at the level of 4% was consistently detected, the
previously reported sensitivity level ranging from 1 to
10% (Cleary et al, 1984; Aisenberg et al, 1987). The
detection of 1 malignant cell in 500 (0.002%) was never
achieved, as claimed in ALL remission marrows (Zenbauer
et al, 1986). The isolation of DNA, especially from solid
tissue, is prone to sampling error if a malignant process
is patchy in distribution and DNA is susceptible to
degradation if there is delay in its extraction. This may
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lead to false negative results. The multistage, complex
nature of the DNA analysis leads to delay in obtaining
results and offers scope for error and difficulties in
interpreting the results. Despite these drawbacks gene
rearrangement studies provided a tumour marker for a
large number of haematological malignancies which could
be used to assess tumour contamination.
5.5.1. Acute leukaemia
Tumour markers as evidenced by gene rearrangements were
found in all 6 patients with B lineage ALL when probed
with IgHJ. This is in agreement with other published
studies (Korsmeyer et al, 1983; Pelicci et al, 1985).
Seventeen per cent of patients with AML had
rearrangements of TCR5 which was considerably less than
in the series reported by Dyer where 18 of 31 patients
(58%) entered into the MRC AML 9 study demonstrated
rearranged bands (Dyer et al, 1988), but more in keeping
with the incidence of 10% found by a Japanese group (Asou
et al, 1989). Of the patients who demonstrated tumour
marker bands with this probe, one had a very immature
phenotype with mixed lineage markers, TdT positivity and
rearrangement of IgHJ, but the other 2 patients were TdT
negative and of the FAB subtypes M2 and .
5.5.2. Lymphoma
All our patients with high and low grade B cell NHL had
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rearrangements in IgHJ confirming the usefulness of Ig
gene rearrangements as a clonal marker(Aisenberg et al,
1987; Henni et al, 1988). One patient with anaplastic T-
NHL who did not demonstate TCR/3 rearrangements had an
undifferentiated tumour which expressed the Ki 1 (CD30)
antigen. These malignancies have shown TCR/3
rearrangements in 10 of 14 reported patients, IgHJ
rearrangements in 3 of 7 reported patients and germline
configuration in 4 of 14 reported patients (Griesser et
al, 1986, Henni et al, 1988). The method used in the
present study had a sensitivity of 4% and may have failed
to detect the low numbers of malignant cells. In patients
with HD no useful tumour markers using gene rearrangement
studies were found. The TCR6 probe was used extensively
as a recent study had suggested a 28% incidence of
rearrangements (Tkachuk et al, 1988), however this was
not confirmed in the present study. The lack of tumour
markers in HD may be due to the low number of Reed-
Sternberg (R-S) cells present in the nodes and it is of
interest that in studies on samples specifically enriched
for these cells or on selected nodes with a high
proportion of R-S cells, IgHJ rearrangements were
occasionally seen (O'Connor et al, 1987; Sundeen et al,
1987).
125
5.6. Gene rearrangements In presentation blood from
patients with NHL
As gene rearrangements were found in the vast majority of
NHL, it was felt that this technique would be a valid one
to employ in assessing peripheral blood involvement with
lymphoma cells. These have been demonstrated in the blood
by morphological assessment (Garrett et al, 1979), clonal
excess (Ault, 1979; Smith et al, 1984) with a sensitivity
of 5 - 10% (Berliner et al, 1986) , and by DNA
hybridisation (Hu et al, 1985), which appeared to be the
most sensitive method (Lindh et al, 1989).
In this study gene rearrangements were found in the
peripheral blood in 19.4% of patients with NHL, more
being found in those with advanced stage of disease (21%)
or with low grade histology (25%). Similar findings have
been reported by Horning in a series of 104 patients with
an overall involvement of 26% (34% in low grades, 16%
high grades, 33% stage III and IV) (Horning et al, 1990),
and a slightly higher percentage reported by Brada with
38% involved overall, 46% of low grades, 31% of high
grades and 54% of stage III and IV) (Brada et al, 1987).
His series, however, included 18 relapsed patients who
tend to have a higher incidence of blood involvement
(Horning et al, 1990). The finding reported here of blood
gene rearrangements in 40% of those with marrow
involvement and 11.5% without histological evidence of
marrow disease is also lower than that found by Brada
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(70% and 30% respectively), but in relatively similar
proportions.
This study also demonstrated the value of gene
rearrangement studies in detecting tumour involvement as
circulating lymphoma cells were found microscopically in
only 29% of patients with positive gene rearrangements in
their blood (27% by Horning and 37% by Brada) and 33% of
patients with positive bone marrows. However, the
significance of peripheral blood gene rearrangements is
not clear, as this finding at diagnosis was not shown to
correlate with a poor prognosis (Horning et al, 1990).
Moreover in the same study, in patients with either high
grade or low grade disease in clinical remission and off
treatment, rearrangements were documented in the blood
in 10% (15 patients) of which only 1 had relapsed after
a median follow up of 24 months. This finding may be
significant for PBSC harvesting especially in steady
state, although no studies have documented the presence
of gene rearrangements in blood whilst undergoing
chemotherapy. In the present study, no gene
rearrangements were found in the PBSC harvests from
patients with lymphoma who were leucapheresed after
chemotherapy.
5.7.Tumour contamination of peripheral blood stem cell
harvests
The absence of gene rearrangements in tumour cells which
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could be used to assess tumour contamination in PBSCH in
the 3 patients with AML and 7 patients with Hodgkin's
disease was a little disappointing but not wholly
unexpected. Although 17% of our AMLs had demonstrated a
TCR6 rearrangement, none of these patients underwent PBSC
harvesting. It may be of value to use the IgHJ probe in
those who were harvested. Likewise in the patients with
HD, IgHJ and TCR5 probes were unhelpful, and TCR/3 was
negative in the one patient studied, although further
work with this probe may have yielded a marker in other
patients.
The lack of rearranged bands in the PBCSH from 11
patients who had tumour markers may seem encouraging. At
the time of harvest one patient with ALL (BM) and one
with low grade NHL (LW) were not in morphological marrow
remission but 2 patients with high grade disease (RB and
MP) appeared to be so. However, in view of the
insensitivity of gene rearrangement studies, if the
presence of malignant cells cannot be detected below even
1 in 100 normals cells this would still represent a
considerable tumour burden (5.6 x 10 cells)
contaminating the harvests which in this study
Q
contained a mean of 5.6 x 10 MNC.
The insensitivity and complexity of Southern blotting
limits its application to the detection of residual
disease. The application of new techniques such as the
PCR, allows the amplification of specific sequences of
128
DNA and can detect as few as 1/10^ to 1/10^ malignant
cells. (d'Auriol et al, 1989; Jonsson et al, 1990). PCR
amplification of TCR6 and gamma sequences has been
successfully applied in ALL (Hasen-Hagge et al, 1989;
d'Auriol et al, 1989), as has amplification of
chromosomal translocations, such as t(14;18), in NHL and
more recently in HD (Stetler Stevenson et al, 1990). The
detection of residual disease by PCR techniques in
peripheral blood stem cell harvests is being investigated
by my collegues. A further advance in the detection of HD
has been reported by the establishment of an in vitro
culture system for the detection of R-S like cells, which
have been found in bone marrow harvests and in 36% of
peripheral blood stem cell harvests (Weisenburger et al,
1990). In neuroblastoma, a non-haematological solid
tumour, a highly specific and sensitive immunocytologic
assay for neuroblastoma cells with a sensitivity of 1 in
5,000 has demonstrated contamination in 14% PBSCH (Moss
et al, 1990).
Although minimal residual disease will be detected using
these very sensitive techniques, the clinical relevance
of low levels of contamination is uncertain and will only
be shown by the appropriate clinical and laboratory
trials.
5.8. Concluding remarks
PBSC represent a viable alternative to bone marrow stem
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cells for autologous transplantation. Standard
chemotherapy regimes used in the treatment of the
majority of patients with acute leukaemias, high grade
non Hodgkin's lymphoma and in two thirds of those with
Hodgkin's disease can induce a rise in CFU-GM at
predictable times. Bone marrow involvement and previous
chemotherapy reduce the peak levels of CFU-GM found in
patients with lymphoma. These progenitors can be
harvested in sufficient numbers for engraftment by well-
timed leukapheresis and they can be cryopreserved without
significant loss of viability. Using gene rearrangement
studies the harvests appeared clear of tumour
contamination.
The role of PBSCT in relation to BMT with regard to
disease control is still uncertain and will only be
clarified as clinical experience grows. The ability to
collect stem cells without the need for a healthy bone
marrow allows intensive therapy to be offered to more
patients. The advantages of more rapid haematopoietic
reconstitution from stem cells collected after
chemotherapy induced mobilisation may reduce the risks of
aplasia associated with transplantation. The use of
combined bone marrow and PBSC transplantation to hasten
haematopoietic recovery is an attractive and successful
option (Bell et al, 1987a; Lopez et al, 1991) which may
serve to reduce the concern over sufficient dose of PBSC
to avoid secondary pancytopenias, particularly
thrombocytopenia.
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Recent developments such as the use of haematopoietic
growth factors to mobilise PBSC, the ability to monitor
rapidly the number of stem cells present in the blood by
flow cytometric immunophenotyping and improvements in
apheresis techniques will serve to make collection of
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